Split (3)

train · 29.5k rows

FEATURE_phases list	FEATURE_enrollmentCount int64	FEATURE_allocation string	FEATURE_interventionModel string	FEATURE_primaryPurpose class label	FEATURE_masking class label	FEATURE_healthyVolunteers bool	FEATURE_sex class label	FEATURE_oversightHasDmc bool	FEATURE_briefSummary string	FEATURE_detailedDescription string	FEATURE_conditions string	FEATURE_conditionsKeywords string	FEATURE_protocolPdfText string	FEATURE_numArms int64	FEATURE_armDescriptions string	FEATURE_armGroupTypes list	FEATURE_numInterventions int64	FEATURE_interventionTypes list	FEATURE_interventionDescriptions string	FEATURE_interventionNames string	FEATURE_numLocations int64	FEATURE_locationDetails string	LABEL_ct_level_ade_population int64	LABEL_sum_dosing_errors int64	LABEL_dosing_error_rate float32	LABEL_wilson_label int64	METADATA_nctId string	METADATA_overallStatus class label	METADATA_completionDate date32	METADATA_startDate date32	METADATA_leadSponsorName string	METADATA_leadSponsorClass class label	METADATA_hasProtocol bool	METADATA_hasSap bool	METADATA_hasIcf bool	METADATA_protocolPdfLinks string	METADATA_count_Accidental overdose int64	METADATA_count_Intentional overdose int64	METADATA_count_Medication error int64	METADATA_count_Overdose int64	METADATA_wilson_lower_bound float32
[ 3 ]	210	RANDOMIZED	PARALLEL	0TREATMENT	4QUADRUPLE	false	0ALL	true	This is a Phase II, multi-center, randomized, double-blind study comparing the safety and efficacy of two doses of BC-3781 versus vancomycin in patients with acute bacterial skin and skin structure infection.	The purpose of the study is to determine the efficacy of 2 dose regimens of BC-3781 versus the licensed medicinal product vancomycin over 5 to 14 days. The population in this study will be patients with an acute bacterial skin and skin structure infection (ABSSSI) and they will receive treatment with one of two doses o...	Bacterial Infections Infection	acute bacterial skin and skin structure infection bacteria	null	3	arm 1: None arm 2: None arm 3: None	[ 0, 0, 1 ]	3	[ 0, 0, 0 ]	intervention 1: BC-3781 dose 100mg is administered as i.v. infusion every 12 h for 5 to 14 days depending on the clinical response. intervention 2: BC-3781 dose 150mg is administered as i.v. infusion every 12 h for 5 to 14 days depending on the clinical response. intervention 3: Vancomycin is administered as i.v. infus...	intervention 1: BC-3781 intervention 2: BC-3781 intervention 3: Vancomycin	9	Chula Vista \| California \| United States \| -117.0842 \| 32.64005 La Mesa \| California \| United States \| -117.02308 \| 32.76783 Oceanside \| California \| United States \| -117.37948 \| 33.19587 Columbus \| Georgia \| United States \| -84.98771 \| 32.46098 Savannah \| Georgia \| United States \| -81.09983 \| 32.08354 Baton Rouge \| Lo...	207	1	0.004831	1	NCT01119105	1COMPLETED	2011-02-03	2010-05-01	Nabriva Therapeutics AG	4INDUSTRY	false	false	false	null	1	0	0	0	0.000853
[ 4 ]	614	RANDOMIZED	PARALLEL	0TREATMENT	4QUADRUPLE	false	0ALL	true	The purpose of the study is to test the efficacy and safety of 2 doses of tanezumab compared to oxycodone CR and placebo in patients with osteoarthritis	This study was terminated on 13 Dec 2010 following a US FDA clinical hold for tanezumab osteoarthritis clinical studies which halted dosing and enrollment of patients on 23 June 2010 for potential safety issues.	Osteoarthritis	monoclonal antibody RN624 PF-04383119 nerve growth factor OA pain arthritis	null	4	arm 1: None arm 2: None arm 3: None arm 4: None	[ 0, 0, 1, 2 ]	4	[ 2, 2, 0, 10 ]	intervention 1: tanezumab 10 mg one dose at weeks 0 and 8 intervention 2: tanezumab 5 mg one dose at weeks 0 and 8 intervention 3: oxycodone CR, 10-40 mg q12h intervention 4: placebo	intervention 1: tanezumab 10 mg intervention 2: tanezumab 5 mg intervention 3: oxycodone intervention 4: placebo	112	Birmingham \| Alabama \| United States \| -86.80249 \| 33.52066 Mobile \| Alabama \| United States \| -88.04305 \| 30.69436 Mobile \| Alabama \| United States \| -88.04305 \| 30.69436 Phoenix \| Arizona \| United States \| -112.07404 \| 33.44838 Beverly Hills \| California \| United States \| -118.40036 \| 34.07362 Buena Park \| California...	610	0	0	0	NCT00985621	6TERMINATED	2011-02-04	2009-10-30	Pfizer	4INDUSTRY	false	false	false	null	0	0	0	0	0
[ 4 ]	1,226	RANDOMIZED	PARALLEL	0TREATMENT	2DOUBLE	false	0ALL	false	The Purpose of this study is to assess the efficacy and safety of two strengths of the FF/GW642444 Inhalation Powder in subject with Chronic Obstructive Pulmonary Disease (COPD)	null	Pulmonary Disease, Chronic Obstructive	COPD Chronic Obstructive Pulmonary Disease Efficacy FEV1 Safety	null	6	arm 1: Inhaled Corticosteroid (ICS) arm 2: Inhaled Corticosteroid (ICS) arm 3: Inhaled Corticosteroid (ICS)/ Long Acting Beta Agonist(LABA) arm 4: Inhaled Corticosteroid (ICS)/ Long Acting Beta Agonist(LABA) arm 5: Long Acting Beta Agonist(LABA) arm 6: Placebo	[ 0, 0, 0, 0, 0, 2 ]	4	[ 0, 0, 0, 0 ]	intervention 1: Inhaled Corticosteroid (ICS) intervention 2: Inhaled Corticosteroid (ICS)/ Long Acting Beta Agonist(LABA) for COPD intervention 3: Long Acting Beta Agonist(LABA) intervention 4: Placebo	intervention 1: FF Inhalation Powder intervention 2: FF/GW642444 Inhalation Powder intervention 3: GW642444 Inhalation Powder intervention 4: Placebo	149	Birmingham \| Alabama \| United States \| -86.80249 \| 33.52066 Jasper \| Alabama \| United States \| -87.27751 \| 33.83122 Lakewood \| California \| United States \| -118.13396 \| 33.85363 Long Beach \| California \| United States \| -118.18923 \| 33.76696 Los Angeles \| California \| United States \| -118.24368 \| 34.05223 Monterey Park...	1,224	0	0	0	NCT01054885	1COMPLETED	2011-02-08	2009-10-19	GlaxoSmithKline	4INDUSTRY	false	false	false	null	0	0	0	0	0
[ 4 ]	727	RANDOMIZED	PARALLEL	0TREATMENT	4QUADRUPLE	false	0ALL	null	This study compared the safety and efficacy of a generic fluticasone furoate (Lek Pharmaceuticals) nasal spray to the reference listed drug in the treatment of seasonal allergic rhinitis. Additionally both the test and the reference formulations were tested for superiority against a placebo nasal spray.	The study was designed as a double-blind, randomized, placebo-controlled, parallel group, multi-site to compare the clinical equivalence of the test formulation of fluticasone furoate, 27.5 mcg/actuation nasal spray (Lek Pharmaceuticals d.d.) with the reference formulation Veramyst® nasal spray (GlaxoSmithKline) in the...	Rhinitis, Allergic, Seasonal	Rhinitis Seasonal Allergic Rhinitis Fluticasone furoate Equivalence Hay fever	null	3	arm 1: Fluticasone furoate 27.5 mcg/actuation nasal spray (Lek Pharmaceuticals) administered once daily at a dose of 110 mcg (4 actuations) for 14 days. arm 2: Fluticasone furoate (Veramyst®) 27.5 mcg/actuation nasal spray administered once daily at a dose of 110 mcg (4 actuations) for 14 days. arm 3: Placebo nasal spr...	[ 0, 1, 2 ]	3	[ 0, 0, 0 ]	intervention 1: Nasal spray administered once daily at a dose of 110 mcg (4 actuations) for 14 days. intervention 2: Nasal spray administered once daily at a dose of 110 mcg (4 actuations) for 14 days. intervention 3: Placebo nasal spray administered once daily (4 actuations) for 14 days.	intervention 1: Fluticasone furoate 27.5 mcg/actuation nasal spray (Lek Pharmaceuticals) intervention 2: Fluticasone furoate (Veramyst®) 27.5 mcg/actuation nasal spray intervention 3: Placebo	7	Austin \| Texas \| United States \| -97.74306 \| 30.26715 Austin \| Texas \| United States \| -97.74306 \| 30.26715 Austin \| Texas \| United States \| -97.74306 \| 30.26715 Kerrville \| Texas \| United States \| -99.14032 \| 30.04743 New Braunfels \| Texas \| United States \| -98.12445 \| 29.703 San Antonio \| Texas \| United States \| -98....	727	0	0	0	NCT01279057	1COMPLETED	2011-02-08	2010-12-27	Sandoz	4INDUSTRY	false	false	false	null	0	0	0	0	0
[ 3 ]	252	RANDOMIZED	PARALLEL	0TREATMENT	2DOUBLE	false	0ALL	null	Study in participants with RA who have an inadequate response to methotrexate.	null	Rheumatoid Arthritis	Autoimmune Diseases Musculoskeletal Diseases Joint Diseases Arthritis Connective Tissue Diseases Arthritis, Rheumatoid Rheumatic Diseases	null	4	arm 1: Placebo on day 1 and weeks 1, 2, 4, 6, 8, and 10 for a total of 7 doses plus a stable weekly dose of methotrexate and folic acid supplementation (at least 5 mg per week). arm 2: 70 mg brodalumab on day 1 and weeks 1, 2, 4, 6, 8, and 10 for a total of 7 doses plus a stable weekly dose of methotrexate and folic ac...	[ 2, 0, 0, 2 ]	4	[ 0, 0, 0, 7 ]	intervention 1: 3 single subcutaneous (SC) injections at day 1 and weeks 1, 2, 4, 6, 8, and 10 intervention 2: 3 single SC injections at day 1 and weeks 1, 2, 4, 6, 8, and 10 intervention 3: Two methotrexate dose adjustments were allowed in the event of methotrexate toxicity, however, doses \< 7.5 mg/week necessitated ...	intervention 1: Brodalumab intervention 2: Placebo intervention 3: Methotrexate intervention 4: folic acid	0	null	252	0	0	0	NCT00950989	1COMPLETED	2011-02-11	2009-12-30	Amgen	4INDUSTRY	false	false	false	null	0	0	0	0	0
[ 2 ]	35	RANDOMIZED	PARALLEL	0TREATMENT	2DOUBLE	false	0ALL	false	This study will assess the safety, tolerability and pharmacokinetics of sitagliptin in 10 to 17 year old diabetic patients.	null	Type 2 Diabetes		null	4	arm 1: Participants were randomized to sitagliptin 50 mg arm 2: Participants were randomized to sitagliptin 100 mg arm 3: Participants were randomized to a single dose of sitagliptin 200 mg arm 4: Participants were randomized to matching placebo to sitagliptin 50 mg, 100 mg, or 200 mg	[ 0, 0, 0, 2 ]	2	[ 0, 0 ]	intervention 1: Participants will fast 8 hours prior to dosing. All doses will be given with 240 ml of water. Participants received either a single oral dose of sitagliptin 50 mg tablet, sitagliptin 100 mg tablet, or sitagliptin 200 mg. intervention 2: Participants will fast 8 hours prior to dosing. All doses will be g...	intervention 1: Sitagliptin phosphate intervention 2: Comparator: matching placebo	0	null	35	0	0	0	NCT00730275	1COMPLETED	2011-02-14	2008-07-18	Merck Sharp & Dohme LLC	4INDUSTRY	false	false	false	null	0	0	0	0	0
[ 5 ]	201	NON_RANDOMIZED	SINGLE_GROUP	0TREATMENT	0NONE	false	0ALL	null	This open-label single arm study will evaluate the efficacy and safety of tocilizumab added to traditional disease-modifying antirheumatic drugs (DMARDs) in patients with moderate to severe active rheumatoid arthritis and an inadequate response to DMARDs. Patients will receive tocilizumab 8 mg/kg by intravenous infusio...	null	Rheumatoid Arthritis		null	1	arm 1: None	[ 0 ]	2	[ 0, 0 ]	intervention 1: 8 mg/kg iv every 4 weeks for 24 weeks intervention 2: stable doses at investigator's prescription	intervention 1: tocilizumab [RoActemra/Actemra] intervention 2: DMARDs (disease-modifying antirheumatic drugs)	28	Chelyabinsk \| N/A \| Russia \| 61.42915 \| 55.15402 Cherkess \| N/A \| Russia \| N/A \| N/A Irkutsk \| N/A \| Russia \| 104.29585 \| 52.29795 Izhevsk \| N/A \| Russia \| 53.20448 \| 56.84976 Kaliningrad \| N/A \| Russia \| 20.51095 \| 54.70649 Kemerovo \| N/A \| Russia \| 86.08333 \| 55.33333 Kirov \| N/A \| Russia \| 49.66007 \| 58.59665 Krasno...	201	0	0	0	NCT00996203	1COMPLETED	2011-02-14	2009-10-31	Hoffmann-La Roche	4INDUSTRY	false	false	false	null	0	0	0	0	0
[ 3 ]	40	NON_RANDOMIZED	PARALLEL	0TREATMENT	0NONE	false	0ALL	false	The main purpose of this study is to assess the effect of a two-week pre-surgery treatment with low-dose temozolomide (TMZ) on brain tumor methylguanine-DNA (deoxyribonucleic acid) methyltransferase (MGMT) activity in patients with gliomas.	null	Glioma		null	2	arm 1: None arm 2: None	[ 0, 4 ]	1	[ 0 ]	intervention 1: Temozolomide 75 mg/m\^2 daily for 14 days prior to surgery. As standard of care, it could also be given at the same dose for up to 28 days after surgery, per investigator discretion.	intervention 1: temozolomide	0	null	40	0	0	0	NCT00424554	1COMPLETED	2011-02-16	2006-09-26	Merck Sharp & Dohme LLC	4INDUSTRY	false	false	false	null	0	0	0	0	0
[ 3 ]	123	RANDOMIZED	PARALLEL	0TREATMENT	0NONE	false	0ALL	null	This randomized phase II trial is studying the side effects and how well giving bevacizumab together with irinotecan or temozolomide works in treating patients with recurrent or refractory glioblastoma multiforme or gliosarcoma. Monoclonal antibodies, such as bevacizumab, can block tumor growth in different ways. Some ...	PRIMARY OBJECTIVES: I. Determine the efficacy of bevacizumab and irinotecan hydrochloride, in terms of 6-month progression-free survival rate, in patients with recurrent or refractory intracranial glioblastoma multiforme or gliosarcoma. II. Determine the adverse event profile and tolerability of bevacizumab and temoz...	Adult Glioblastoma Adult Gliosarcoma Recurrent Adult Brain Neoplasm		null	2	arm 1: Patients receive bevacizumab IV over 30-90 minutes on days 1 and 15 and oral temozolomide once daily on days 1-21. arm 2: Patients receive bevacizumab IV as in Arm I followed by irinotecan hydrochloride IV over 90 minutes on days 1 and 15.	[ 0, 0 ]	3	[ 2, 0, 0 ]	intervention 1: Given IV intervention 2: Given IV intervention 3: Given orally	intervention 1: Bevacizumab intervention 2: Irinotecan Hydrochloride intervention 3: Temozolomide	93	Mobile \| Alabama \| United States \| -88.04305 \| 30.69436 Fairbanks \| Alaska \| United States \| -147.71639 \| 64.83778 Scottsdale \| Arizona \| United States \| -111.89903 \| 33.50921 Berkeley \| California \| United States \| -122.27275 \| 37.87159 Burlingame \| California \| United States \| -122.36608 \| 37.5841 Concord \| Californi...	117	0	0	0	NCT00433381	1COMPLETED	2011-02-16	2007-03-01	National Cancer Institute (NCI)	0NIH	false	false	false	null	0	0	0	0	0
[ 3 ]	260	RANDOMIZED	PARALLEL	0TREATMENT	4QUADRUPLE	false	0ALL	false	Osteoarthritis (OA) is the most common form of arthritis. It can cause pain, swelling, and reduced motion in the joints. That can reduce quality of life. OA can occur in any joint, but usually affects the hands, knees, hips or spine. The purpose of this study is to find out if doctors might be able to use 2% PENNSAID...	null	Osteoarthritis of the Knee	Osteoarthritis Arthritis NSAIDs Topical NSAID Diclofenac PENNSAID	null	2	arm 1: Diclofenac sodium 2.0% w/w arm 2: The complete carrier containing ingredients at the same concentrations as experimental arm without diclofenac sodium	[ 0, 2 ]	2	[ 0, 0 ]	intervention 1: 2 mL applied to the front, back and sides of the knee twice a day (morning and night) for 4 weeks intervention 2: 2 mL applied to the front, back and sides of the knee twice a day (morning and night) for 4 weeks	intervention 1: PENNSAID Gel intervention 2: Vehicle	26	Tucson \| Arizona \| United States \| -110.92648 \| 32.22174 Sacramento \| California \| United States \| -121.4944 \| 38.58157 Clearwater \| Florida \| United States \| -82.8001 \| 27.96585 DeLand \| Florida \| United States \| -81.30312 \| 29.02832 St. Petersburg \| Florida \| United States \| -82.67927 \| 27.77086 Marietta \| Georgia \| ...	259	0	0	0	NCT01119898	1COMPLETED	2011-02-16	2010-08-02	Mallinckrodt	4INDUSTRY	false	false	false	null	0	0	0	0	0
[ 4 ]	7	NA	SINGLE_GROUP	0TREATMENT	0NONE	false	0ALL	null	This study will examine whether a medicine called canakinumab is safe and effective for treating patients with neonatal-onset multisystem inflammatory disease (NOMID), also known as chronic infantile neurologic, cutaneous, articular (CINCA) syndrome. This disease can cause rash, joint deformities, brain inflammation, p...	This open-label study was designed to investigate the safety, tolerability, efficacy, pharmacokinetics and pharmacodynamics of canakinumab, a fully human anti-interleukin-1beta (anti-IL-1beta) monoclonal antibody, in patients with NOMID / CINCA syndrome. A total of 25 to 30 patients will be enrolled into the study. The...	NOMID CINCA Syndrome	NOMID CINCA Syndrome Canakinumab	null	1	arm 1: Participants received body-weight stratified dosage of canakinumab treatment at 300 milligrams (mg) (for participants weighing more than 40 kilograms (kg)) and at 2 mg/kg (for participants weight less than or equal to 40 kg) subcutaneously every 4-8 weeks as per investigator discretion for a treatment period of ...	[ 0 ]	1	[ 0 ]	intervention 1: None	intervention 1: Canakinumab	1	Bethesda \| Maryland \| United States \| -77.10026 \| 38.98067	6	0	0	0	NCT00770601	6TERMINATED	2011-02-17	2009-01-26	Novartis Pharmaceuticals	4INDUSTRY	false	false	false	null	0	0	0	0	0
[ 3 ]	195	RANDOMIZED	PARALLEL	0TREATMENT	4QUADRUPLE	false	0ALL	false	The primary objective of this study is to assess the safety and efficacy of different dose regimens of ILV-094 compared with placebo, administered subcutaneously to subjects with active rheumatoid arthritis who are taking methotrexate.	null	Rheumatoid Arthritis	Rheumatoid Arthritis ACR Methotrexate Interleukin-22	null	5	arm 1: Part 1: Placebo arm 2: Part 1: 100 mg ILV-094 SC Q4W arm 3: Part 1: 100 mg ILV-094 SC Q2W arm 4: None arm 5: Part 2: 200 mg ILV-094 SC Q2W	[ 2, 0, 0, 2, 0 ]	5	[ 10, 0, 0, 10, 0 ]	intervention 1: Part 1: Placebo SC administration every 2 weeks X 10 weeks. intervention 2: Part 1: ILV-094 100 mg SC every 4 weeks (alternating ILV-094 100 mg and placebo every 2 weeks) X 10 weeks. intervention 3: Part 1: ILV-094 100 mg SC every 2 weeks X 10 weeks. intervention 4: Part 2: Placebo SC administration eve...	intervention 1: Placebo intervention 2: ILV-094 intervention 3: ILV-094 intervention 4: Placebo intervention 5: ILV-094	52	Glendale \| Arizona \| United States \| -112.18599 \| 33.53865 Palm Desert \| California \| United States \| -116.37697 \| 33.72255 Palm Harbor \| Florida \| United States \| -82.76371 \| 28.07807 Sarasota \| Florida \| United States \| -82.53065 \| 27.33643 Sarasota \| Florida \| United States \| -82.53065 \| 27.33643 Indianapolis \| Indi...	195	0	0	0	NCT00883896	1COMPLETED	2011-02-18	2009-06-18	Pfizer	4INDUSTRY	false	false	false	null	0	0	0	0	0
[ 3 ]	108	RANDOMIZED	CROSSOVER	0TREATMENT	2DOUBLE	false	0ALL	null	To investigate the effectiveness and safety of BI 671800 given in the morning (AM), evening (PM) or twice daily (b.i.d.) compared too placebo as add on therapy to inhaled corticosteroid in symptomatic asthma patients.	null	Asthma		null	4	arm 1: Patients receiving two capsules twice daily arm 2: Patients receiving four capsules in the morning arm 3: Patients receiving four capsules in the evening arm 4: Patients receiving four capsules twice a day	[ 0, 0, 0, 2 ]	2	[ 0, 0 ]	intervention 1: BI 671800 intervention 2: Placebo matching BI 671800	intervention 1: BI 671800 intervention 2: Placebo	14	Huntington Beach \| California \| United States \| -117.99923 \| 33.6603 Mission Viejo \| California \| United States \| -117.672 \| 33.60002 Stockton \| California \| United States \| -121.29078 \| 37.9577 Colorado Springs \| Colorado \| United States \| -104.82136 \| 38.83388 Denver \| Colorado \| United States \| -104.9847 \| 39.73915 ...	309	0	0	0	NCT01090024	1COMPLETED	2011-02-18	2010-03-01	Boehringer Ingelheim	4INDUSTRY	false	false	false	null	0	0	0	0	0
[ 2, 3 ]	5	RANDOMIZED	PARALLEL	0TREATMENT	0NONE	false	0ALL	false	The purpose of the Phase Ib portion is to find out the highest dose of study drug that can safely be given when tested in a small group of subjects. The purpose of the Phase II portion is to find out how safe the study drug is when taken at the highest dose in a larger group of subjects.	The primary purpose for Phase 1b: to determine the maximum tolerated dose (MTD) of E7820 recommended for Phase 2 when administered in combination with the FOLFIRI regimen (irinotecan, leucovorin, and 5-fluorouracil \[5-FU\]) in participants with locally advanced or metastatic colorectal cancer (mCRC) who have failed fi...	Colorectal Cancer		null	3	arm 1: The FOLFIRI regimen consists of irinotecan at 180 mg/m2 (IV infusion) on Day 1 and Day 15 of each 28-day cycle, leucovorin at 200 mg/m2 (400 mg/m2 if using d,l-racemic mixture of leucovorin) by IV infusion on Days 1 and 15 of each cycle, and 5-FU at 400 mg/m2 as an IV bolus injection followed by a total of 2400 ...	[ 1, 0, 0 ]	3	[ 0, 0, 0 ]	intervention 1: FOLFIRI will be administered as IV infusion on Days 1 and 15 of each cycle, and 5-FU at 400 mg/m\^2 as an IV bolus injection followed by a total of 2400 mg/m2 by CIV infusion over 46 hours over Days 1 and 2 via an ambulatory programmable pump. The 5-FU IV bolus (400 mg/m\^2) and CIV infusion (2400 mg/m\...	intervention 1: FOLFIRI intervention 2: E7820 intervention 3: Bevacizumab	34	Denver \| Colorado \| United States \| -104.9847 \| 39.73915 Berkeley Heights \| New Jersey \| United States \| -74.44265 \| 40.68343 Mount Holly \| New Jersey \| United States \| -74.78766 \| 39.99289 Chapel Hill \| North Carolina \| United States \| -79.05584 \| 35.9132 Dallas \| Texas \| United States \| -96.80667 \| 32.78306 Tacoma \| ...	5	0	0	0	NCT01133990	6TERMINATED	2011-02-18	2010-03-04	Eisai Inc.	4INDUSTRY	false	false	false	null	0	0	0	0	0
[ 4 ]	271	RANDOMIZED	PARALLEL	9OTHER	1SINGLE	false	1FEMALE	false	Iron deficiency anaemia (Haemoglobin, Hb \< 12gm/dl) is one of India's major public health problems particularly in women. Effective control of iron deficiency anaemia decreases the incidence of fatigue, bodyache, headache, lack of concentration and menstrual complications. Iron bisglycine chelate has been used success...	Rationale Iron deficiency is the most common form of malnutrition globally. In India, nearly 70% of women are estimated to be iron deficient. Iron deficiency anemia (IDA, Hb \<12gm/dl) is a very late manifestation of iron deficiency. IDA is a consequence of decreased iron intake, increased iron loss from the body or in...	Haematopoiesis		null	3	arm 1: ferrous bisglycinate chelate 1 tablet daily arm 2: ferrous ascorbate, 1 tablet daily arm 3: ferrous bisglycinate chelate 2 tablets daily	[ 0, 1, 0 ]	3	[ 0, 7, 7 ]	intervention 1: 100 mg elemental iron intervention 2: 60 mg elemental iron intervention 3: 120 mg elemental iron	intervention 1: ferrous ascorbate intervention 2: ferrous bisglycinate chelate 1 OD intervention 3: ferrous bisglycinate chelate 2 OD	7	Bhojipura, Bareilly \| N/A \| India \| N/A \| N/A Lucknow \| N/A \| India \| 80.92313 \| 26.83928 Lucknow \| N/A \| India \| 80.92313 \| 26.83928 Nagpur \| N/A \| India \| 79.08491 \| 21.14631 Pune \| N/A \| India \| 73.85535 \| 18.51957 Surat \| N/A \| India \| 72.83023 \| 21.19594 Thane,Mumbai \| N/A \| India \| N/A \| N/A	270	0	0	0	NCT01160198	1COMPLETED	2011-02-18	2010-10-13	GlaxoSmithKline	4INDUSTRY	false	false	false	null	0	0	0	0	0
[ 2 ]	87	NON_RANDOMIZED	PARALLEL	0TREATMENT	0NONE	false	0ALL	false	To determine the dose-limiting toxicity (DLT) and maximum tolerated dose (MTD) of MLN8237 when given by mouth (PO) for a minimum of 7 and a maximum of 21 consecutive days, followed by a 14-day recovery period.	The drug tested in this study is called alisertib. Alisertib is being tested to treat people who have advanced malignancies. This study determined the dose-limiting toxicity, maximum tolerated dose, safety and pharmacokinetics (how the drug moves through the body) for alisertib when given once or twice a day for 7 to 2...	Advanced Malignancies	Drug therapy	null	3	arm 1: Alisertib 5, 10, 20, 40, 80, 110 or 150 mg, Powder-in-Capsule (PIC) formulation, orally, once daily (QD) for 7 to 21 days followed by a 14--day recovery period in each cycle until disease progression or unacceptable alisertib--related toxicity (up to 51 cycles). arm 2: Alisertib 10 or 20 mg, Enteric-coated Table...	[ 0, 0, 0 ]	1	[ 0 ]	intervention 1: Alisertib (MLN8237) will be supplied in capsules of 5 or 25 mg and will be given on an empty stomach, with patients remaining nothing by mouth except for water and prescribed medications for 2 hours before and 1 hour after each dose. Each dose will be given by mouth with 8 ounces of water for 7 to 21 co...	intervention 1: Alisertib	1	Nashville \| Tennessee \| United States \| -86.78444 \| 36.16589	87	0	0	0	NCT00500903	1COMPLETED	2011-02-23	2007-05-15	Millennium Pharmaceuticals, Inc.	4INDUSTRY	false	false	false	null	0	0	0	0	0
[ 0 ]	1	RANDOMIZED	PARALLEL	0TREATMENT	2DOUBLE	false	0ALL	false	Cardiovascular disease and mortality is the largest comorbidity within the dialysis population. Nearly 50% of hemodialysis patients will have congestive heart failure at initiation. According to the most recent United States Renal Data System (USRDS), 40% of incident dialysis patients will have a cardiovascular event o...	Cardiovascular disease and mortality is the largest comorbidity within the dialysis population. Nearly 50% of hemodialysis patients will have congestive heart failure at initiation. According to the most recent USRDS data, 40% of incident dialysis patients will have a cardiovascular event or die within the first 9 mon...	Cardiovascular Disease	heart rate variability Dialysis	null	2	arm 1: 4 capsules inert oil Placebo each day for 16 weeks arm 2: 4 capsules Omega-3 Fatty Acid Esters each day for 16 weeks	[ 2, 1 ]	2	[ 0, 0 ]	intervention 1: 1 gram capsules Omega-3 Acid Ethyl Esters for a total of 4 grams (4 capsules) per day for 16 weeks intervention 2: 4 capsules each day for 16 weeks	intervention 1: Omega-3 Acid Ethyl Esters intervention 2: Placebo	1	Iowa City \| Iowa \| United States \| -91.53017 \| 41.66113	1	0	0	0	NCT01002118	6TERMINATED	2011-02-23	2008-01-25	University of Iowa	7OTHER	false	false	false	null	0	0	0	0	0
[ 2 ]	12	NA	SINGLE_GROUP	0TREATMENT	0NONE	false	0ALL	false	The purpose of this study is to determine the maximum tolerated dose (MTD) of poly (ADP-Ribose) polymerase inhibitor E7016 when used with temozolomide (TMZ) in patients with advanced solid tumors and gliomas.	null	Solid Tumors		null	1	arm 1: None	[ 0 ]	1	[ 0 ]	intervention 1: Single-Dose PK Period (single oral dose of E7016 on Day -7) in the Dose-Escalation Component; Multiple-Dose Treatment Cycles (7 days of oral E7016 + 5 days of oral TMZ) added in Cycle 1 of the Dose-Escalation Component and in Cycles 1 through 6 of the Expansion Component.	intervention 1: E7016 + TMZ	5	Boston \| Massachusetts \| United States \| -71.05977 \| 42.35843 Lebanon \| New Hampshire \| United States \| -72.25176 \| 43.64229 Greenville \| South Carolina \| United States \| -82.39401 \| 34.85262 San Antonio \| Texas \| United States \| -98.49363 \| 29.42412 Charlottesville \| Virginia \| United States \| -78.47668 \| 38.02931	12	0	0	0	NCT01127178	6TERMINATED	2011-02-24	2010-03-29	Eisai Inc.	4INDUSTRY	false	false	false	null	0	0	0	0	0
[ 2, 3 ]	59	NON_RANDOMIZED	SINGLE_GROUP	0TREATMENT	0NONE	false	0ALL	true	RATIONALE: Drugs used in chemotherapy, such as docetaxel, oxaliplatin, and fluorouracil, work in different ways to stop the growth of tumor cells, either by killing the cells or by stopping them from dividing. Giving more than one drug (combination chemotherapy) may kill more tumor cells. PURPOSE: This phase I/II tria...	OBJECTIVES: Primary * To establish the maximum tolerated dose of docetaxel when administered with oxaliplatin and fluorouracil in patients with metastatic or unresectable solid tumors. (Phase I) * To determine the response rate in patients with metastatic or unresectable adenocarcinoma of the stomach or gastroesophag...	Gastric Cancer Unspecified Adult Solid Tumor, Protocol Specific	unspecified adult solid tumor, protocol specific adenocarcinoma of the stomach stage III gastric cancer stage IV gastric cancer	null	5	arm 1: Docetaxel 25 mg/m2 + oxaliplatin 85 mg/m2 + 5-Fluorouracil 2.4 gm/m2 arm 2: Docetaxel 30 mg/m2 + oxaliplatin 85 mg/m2 + 5-Fluorouracil 2.4 gm/m2 arm 3: Docetaxel 40 mg/m2 + oxaliplatin 85 mg/m2 + 5-Fluorouracil 2.4 gm/m2 arm 4: Docetaxel 50 mg/m2 + oxaliplatin 85 mg/m2 + 5-Fluorouracil 2.4 gm/m2 arm 5: Docetaxel...	[ 0, 0, 0, 0, 0 ]	3	[ 0, 0, 0 ]	intervention 1: Docetaxel at the dose indicated by the patient cohort, administered intravenously in 5% dextrose over 1 hour on day 1 of each cycle. intervention 2: Intravenous infusion at 85 mg/m2 continuously over 46 hours beginning each cycle after docetaxel administration. intervention 3: Oxaliplatin 2.4 gm/m2 admi...	intervention 1: docetaxel intervention 2: fluorouracil intervention 3: oxaliplatin	1	Chicago \| Illinois \| United States \| -87.65005 \| 41.85003	58	0	0	0	NCT00711243	1COMPLETED	2011-02-25	2005-04-20	Northwestern University	7OTHER	false	false	false	null	0	0	0	0	0
[ 2, 3 ]	31	NON_RANDOMIZED	SEQUENTIAL	0TREATMENT	0NONE	false	0ALL	true	This is a Phase I/II study of a drug called bortezomib given in combination with chemotherapy drugs used to treat acute lymphoblastic leukemia (ALL) that has come back (recurred). Bortezomib is a drug that has been approved by the Food and Drug Administration (FDA) for treating adults with multiple myeloma which is a t...	All patients will receive 1 course of chemotherapy unless medical complications prevent the administration of some of the drugs. Treatment will last about 1 month. Treatment on this study will consist of a combination of 7 anti-cancer medications. The 7 anti-cancer medicines are bortezomib, vincristine, dexamethasone,...	Acute Lymphoblastic Leukemia	Acute Lymphoblastic Leukemia Pediatrics Relapsed Recurrence Bortezomib Velcade Therapeutic Advances in Childhood Leukemia Investigational Childhood ALL Relapsed ALL Refractory ALL Relapsed pediatric ALL Refractory pediatric ALL TACL Recurrent Pediatric ALL	null	2	arm 1: Intervention: Bortezomib with chemotherapy (dexamethasone, PEG-asparaginase, doxorubicin, cytarabine, methotrexate, and vincristine) and Triple IT therapy for patients who are CNS 2 or 3 at study entry. 3+3 escalation design. arm 2: Intervention: Bortezomib with chemotherapy (dexamethasone, PEG-asparaginase, dox...	[ 0, 0 ]	8	[ 0, 0, 0, 0, 0, 0, 0, 0 ]	intervention 1: Intravenous on days 1, 4, 8 and 11. Dose assigned at study entry. intervention 2: 10 mg/m2/day divided BID, oral administration for 14 days. intervention 3: 2500 IU/m2/day, intramuscular injection on Days 2, 8, 15 and 22 intervention 4: 60 mg/m2/day IV over 15 minutes on Day 1 intervention 5: Given intr...	intervention 1: Bortezomib intervention 2: Dexamethasone intervention 3: PEG-asparaginase intervention 4: Doxorubicin intervention 5: Cytarabine intervention 6: Methotrexate intervention 7: Vincristine intervention 8: Triple IT Therapy	24	Duarte \| California \| United States \| -117.97729 \| 34.13945 Long Beach \| California \| United States \| -118.18923 \| 33.76696 Los Angeles \| California \| United States \| -118.24368 \| 34.05223 Oakland \| California \| United States \| -122.2708 \| 37.80437 Palo Alto \| California \| United States \| -122.14302 \| 37.44188 San Fran...	31	0	0	0	NCT00440726	1COMPLETED	2011-02-26	2006-08-04	Therapeutic Advances in Childhood Leukemia Consortium	7OTHER	false	false	false	null	0	0	0	0	0
[ 4 ]	529	RANDOMIZED	PARALLEL	0TREATMENT	4QUADRUPLE	false	0ALL	false	Subjects with perennial allergic rhinitis will be randomized to 320 mcg of beclomethasone dipropionate (BDP) using a hydrofluoroalkane (HFA) propellant or placebo as a nasal aerosol. The subjects will be followed for safety and efficacy for a period of 30 or 52 weeks. BDP HFA is a steroid which is currently FDA approve...	null	Rhinitis, Allergic, Perennial	Rhinitis, Allergic, Perennial BDP-HFA Hay fever Allergic rhinitis	null	2	arm 1: During the 30-week (or 52-week, depending upon investigator site) double-blind Treatment Period participants self-administered 4 actuations (two per nostril) of 80 µg BDP HFA once daily each morning. arm 2: During the 30-week (or 52-week, depending upon investigator site) double-blind Treatment Period participan...	[ 0, 2 ]	2	[ 0, 0 ]	intervention 1: Total daily dose of 320 micrograms per day of beclomethasone dipropionate (BDP) hydrofluoroalkane (HFA) applied as a nasal aerosol each morning for 30-weeks (or 52-weeks, depending upon investigator site). intervention 2: Placebo nasal aerosol administered daily for 30-weeks (or 52-weeks, depending upon...	intervention 1: Beclomethasone dipropionate intervention 2: Placebo Nasal Aerosol	34	Oxford \| Alabama \| United States \| -85.83496 \| 33.61427 Encinitas \| California \| United States \| -117.29198 \| 33.03699 Huntington Beach \| California \| United States \| -117.99923 \| 33.6603 San Diego \| California \| United States \| -117.16472 \| 32.71571 Stockton \| California \| United States \| -121.29078 \| 37.9577 Colorado...	526	0	0	0	NCT00988247	1COMPLETED	2011-02-28	2009-10-31	Teva Branded Pharmaceutical Products R&D, Inc.	4INDUSTRY	false	false	false	null	0	0	0	0	0
[ 4 ]	626	RANDOMIZED	PARALLEL	0TREATMENT	0NONE	false	0ALL	true	The primary objective of this study is efficacy. The primary efficacy endpoint of this study is a comparison of the overall survival of subjects treated with CCI-779 \[Temsirolimus\], administered intravenously \[IV\] once weekly and the combination of CCI-779, administered IV once weekly with Interferon Alfa \[IFN alf...	null	Carcinoma, Renal Cell Kidney Neoplasms	Advanced Renal Cell Carcinoma Kidney Cancer	null	3	arm 1: None arm 2: None arm 3: None	[ 1, 0, 0 ]	3	[ 0, 0, 0 ]	intervention 1: Interferon alfa (Roferon) 3 MU given Sub Cutaneously three time /week for the first week, 9 MU given Sub Cutaneously three time /week for the second week, 18 MU given Sub Cutaneously three time /week thereafter. intervention 2: 25 mg of CCI-779 given Intra Venously once per week intervention 3: 15 mg of...	intervention 1: Interferon Alfa intervention 2: CCI-779 intervention 3: Interferon Alfa and CCI-779	153	Little Rock \| Arkansas \| United States \| -92.28959 \| 34.74648 La Verne \| California \| United States \| -117.76784 \| 34.10084 Los Angeles \| California \| United States \| -118.24368 \| 34.05223 San Diego \| California \| United States \| -117.16472 \| 32.71571 San Francisco \| California \| United States \| -122.41942 \| 37.77493 W...	616	5	0.008117	1	NCT00065468	1COMPLETED	2011-03-01	2003-07-01	Pfizer	4INDUSTRY	false	false	false	null	1	0	1	3	0.003472
[ 4 ]	1,221	RANDOMIZED	PARALLEL	0TREATMENT	0NONE	false	0ALL	true	Drugs used against cancer work in different ways to stop the growth of tumor cells, either by killing the cells or by stopping them from dividing. Monoclonal antibodies, such as cetuximab, can block tumor growth in different ways. Giving combination chemotherapy together with cetuximab as first treatment after diagnosi...	null	Epidermal Growth Factor Receptor (EGFR) Expressing Metastatic Colorectal Cancer	Metastatic colorectal cancer EGFR Irinotecan cetuximab first-line treatment	null	2	arm 1: None arm 2: None	[ 0, 1 ]	2	[ 0, 0 ]	intervention 1: Cetuximab intravenous infusion of 400mg/m\^2 for the first infusion then weekly intravenous infusion of 250mg/m\^2. Number of Cycles: until progression or unacceptable toxicity develops intervention 2: Bi-weekly Irinotecan infusion of 180mg/m\^2, Folinic Acid infusion of 400mg/m\^2 (racemic) or 200mg/m\...	intervention 1: Cetuximab intervention 2: FOLFIRI (5-Fluorouracil, Folinic acid, Irinotecan)	154	Buenos Aires \| N/A \| Argentina \| -58.37723 \| -34.61315 Bedford Park \| N/A \| Australia \| 138.56815 \| -35.02204 Darlinghurst \| N/A \| Australia \| 151.21925 \| -33.87939 Heidelberg \| N/A \| Australia \| 145.06667 \| -37.75 Nedlands \| N/A \| Australia \| 115.8073 \| -31.98184 West Perth \| N/A \| Australia \| 115.84199 \| -31.94896 Wo...	1,202	1	0.000832	1	NCT00154102	1COMPLETED	2011-03-01	2004-05-01	Merck KGaA, Darmstadt, Germany	4INDUSTRY	false	false	false	null	0	0	0	1	0.000147
[ 4 ]	109	NON_RANDOMIZED	SINGLE_GROUP	1PREVENTION	0NONE	false	0ALL	false	The purpose of this clinical research study is to learn if the study drug entecavir will prevent the recurrence of hepatitis B virus (HBV) in participants who receive an orthotopic liver transplant (OLT) due to HBV infection.	null	Hepatitis B, Chronic	Chronic Hepatitis B Virus, Liver Transplant	null	1	arm 1: None	[ 0 ]	1	[ 0 ]	intervention 1: Tablets, Oral, 1 mg, once daily, up to 72 weeks	intervention 1: entecavir	32	Chicago \| Illinois \| United States \| -87.65005 \| 41.85003 New Orleans \| Louisiana \| United States \| -90.07507 \| 29.95465 Rochester \| Minnesota \| United States \| -92.4699 \| 44.02163 Omaha \| Nebraska \| United States \| -95.94043 \| 41.25626 Rochester \| New York \| United States \| -77.61556 \| 43.15478 Cincinnati \| Ohio \| Uni...	65	1	0.015385	1	NCT00395018	1COMPLETED	2011-03-01	2007-04-01	Bristol-Myers Squibb	4INDUSTRY	false	false	false	null	0	0	0	1	0.002721
[ 4 ]	306	RANDOMIZED	PARALLEL	0TREATMENT	4QUADRUPLE	false	0ALL	false	The purpose of this study is to evaluate the effects of losartan on proteinuria in pediatric patients.	The study included a 12-week double-blind treatment phase and a 36-month open-label extension phase. Participants who completed or discontinued the initial 12-week phase of the study and who opted to participate in the open label extension phase were randomized to either losartan or enalapril at a dose of the investiga...	Proteinuria		null	4	arm 1: Normotensive participants received losartan. Hypertensive participants received either active losartan (plus amlodipine placebo) OR active amlodipine (plus losartan placebo). arm 2: Hypertensive participants were randomized to receive either active losartan (plus amlodipine placebo) OR active amlodipine (plus l...	[ 0, 1, 0, 1 ]	6	[ 0, 10, 0, 10, 10, 0 ]	intervention 1: Losartan Use During the Double-Blind Treatment Phase: Losartan potassium was administered orally as tablets; 25 or 50 milligrams (mg); or as a liquid suspension 2.5 mg/mL prepared for participants who weighed less than 25 kilograms (kg) or for those participants unable to swallow tablets. During the do...	intervention 1: Losartan Potassium intervention 2: Comparator: Placebo (Losartan) intervention 3: Comparator: amlodipine besylate intervention 4: Comparator: Placebo (amlodipine besylate) intervention 5: Placebo (Losartan) intervention 6: Enalapril Maleate	0	null	574	1	0.001742	1	NCT00568178	1COMPLETED	2011-03-01	2007-06-01	Organon and Co	4INDUSTRY	false	false	false	null	0	0	0	1	0.000308
[ 4 ]	304	NA	SINGLE_GROUP	0TREATMENT	0NONE	false	0ALL	false	The primary objective of this study is to evaluate the long-term safety of desvenlafaxine succinate sustained release tablets during 10-month open-label treatment of Japanese subjects with major depressive disorder (MDD). The secondary objective is to evaluate the long-term response of subjects receiving desvenlafaxin...	null	Major Depressive Disorder	Open-label Long-term extension study	null	1	arm 1: DVS SR	[ 0 ]	1	[ 0 ]	intervention 1: 25-mg or 50-mg DVS SR tablets taken orally, once daily, at the same time each day. 100 mg dose will be supplied as 2 tablets of 50-mg tablet.	intervention 1: desvenlafaxine succinate sustained release tablets	17	Aichi \| N/A \| Japan \| 130.62158 \| 32.51879 Chiba \| N/A \| Japan \| 140.11667 \| 35.6 Fukuoka \| N/A \| Japan \| 130.41667 \| 33.6 Fukushima \| N/A \| Japan \| 140.46667 \| 37.75 Gunma \| N/A \| Japan \| N/A \| N/A Hiroshima \| N/A \| Japan \| 132.45 \| 34.4 Hokkaido \| N/A \| Japan \| N/A \| N/A Hyōgo \| N/A \| Japan \| 144.43333 \| 43.36667 Ish...	304	1	0.003289	1	NCT00831415	1COMPLETED	2011-03-01	2009-03-01	Pfizer	4INDUSTRY	false	false	false	null	0	1	0	0	0.000581
[ 4 ]	7,484	RANDOMIZED	PARALLEL	1PREVENTION	3TRIPLE	false	0ALL	true	The purpose of this study is to determine if apixaban is superior to placebo for preventing cardiovascular death, non-fatal myocardial infarction, or ischemic stroke in subjects with a recent acute coronary syndrome	null	Acute Coronary Syndrome	NOS	null	2	arm 1: None arm 2: None	[ 1, 2 ]	2	[ 0, 0 ]	intervention 1: Tablets, Oral, 5 mg, twice daily, until study end intervention 2: Tablets, Oral, 0 mg, twice daily, until study end	intervention 1: Apixaban intervention 2: Placebo	1,012	Birmingham \| Alabama \| United States \| -86.80249 \| 33.52066 Birmingham \| Alabama \| United States \| -86.80249 \| 33.52066 Huntsville \| Alabama \| United States \| -86.58594 \| 34.7304 Phoenix \| Arizona \| United States \| -112.07404 \| 33.44838 Fort Smith \| Arkansas \| United States \| -94.39855 \| 35.38592 Jonesboro \| Arkansas \|...	7,315	9	0.00123	1	NCT00831441	6TERMINATED	2011-03-01	2009-03-01	Bristol-Myers Squibb	4INDUSTRY	false	false	false	null	7	0	0	2	0.000647
[ 4 ]	874	RANDOMIZED	PARALLEL	0TREATMENT	4QUADRUPLE	false	0ALL	false	The primary purpose of this study is to compare the long-term efficacy and safety of desvenlafaxine succinate sustained release versus placebo in adults with Major Depressive Disorder, using a randomized withdrawal design. Randomized withdrawal means that after receiving desvenlafaxine succinate sustained release for a...	null	Major Depressive Disorder	Major Depressive Disorder	null	2	arm 1: None arm 2: None	[ 0, 2 ]	3	[ 0, 0, 0 ]	intervention 1: 50 mg tablet, once daily. 5 months open-label duration for all enrolled subjects; additional 6 months double-blind duration for randomized subjects assigned to this arm. intervention 2: 25 mg tablet for taper, once daily for 1 week intervention 3: Matching placebo tablet, once daily. 6 months double-bli...	intervention 1: Desvenlafaxine succinate sustained release 50 mg intervention 2: Desvenlafaxine succinate sustained release 25 mg intervention 3: Placebo	90	Beverly Hills \| California \| United States \| -118.40036 \| 34.07362 Encino \| California \| United States \| -118.50119 \| 34.15917 Los Alamitos \| California \| United States \| -118.07256 \| 33.80307 Orange \| California \| United States \| -117.85311 \| 33.78779 Upland \| California \| United States \| -117.64839 \| 34.09751 Aurora ...	2,955	2	0.000677	1	NCT00887224	1COMPLETED	2011-03-01	2009-06-01	Pfizer	4INDUSTRY	false	false	false	null	0	2	0	0	0.000186
[ 3 ]	342	RANDOMIZED	PARALLEL	0TREATMENT	2DOUBLE	false	0ALL	true	RATIONALE: Preclinical studies indicate that sorafenib is a potent inhibitor of Raf kinase in vitro and in vivo, with significant dose-dependent, anti-tumor activity in four different human tumor types including colon, pancreatic, lung, and ovarian. This activity was cytostatic in nature and was maintained if dosing wa...	OBJECTIVES: * To determine the percent of patients maintaining stable disease or objective response two months after randomization with continued sorafenib treatment, compared to patients switched to placebo. * To determine progression-free survival, overall survival, and response rate. OUTLINE: This is a randomized,...	Lung Cancer	recurrent non-small cell lung cancer stage IIIB non-small cell lung cancer stage IV non-small cell lung cancer sorafenib	null	3	arm 1: Induction: All patients receive oral sorafenib twice daily on days 1-28. Treatment continues for 2 cycles in the absence of disease progression or unacceptable toxicity. Patients with stable disease proceed to randomization. Patients with responding disease continue to receive sorafenib for up to 1 year in the a...	[ 0, 2, 5 ]	2	[ 0, 0 ]	intervention 1: Step 1 (induction): Sorafenib was giventwice daily for two cycles to all patients. Patients with progression (PD) discontinued treatment. Those who responded after two cycles continued treatment up to 1 year or until PD. With response after 1 year, patients were given the option to continue treatment un...	intervention 1: Sorafenib intervention 2: Placebo	141	Stanford \| California \| United States \| -122.16608 \| 37.42411 Aurora \| Colorado \| United States \| -104.83192 \| 39.72943 Boulder \| Colorado \| United States \| -105.27055 \| 40.01499 Colorado Springs \| Colorado \| United States \| -104.82136 \| 38.83388 Denver \| Colorado \| United States \| -104.9847 \| 39.73915 Denver \| Colorad...	463	0	0	0	NCT00064350	1COMPLETED	2011-03-01	2004-06-28	Eastern Cooperative Oncology Group	5NETWORK	false	false	false	null	0	0	0	0	0
[ 3 ]	61	NA	SINGLE_GROUP	0TREATMENT	0NONE	false	0ALL	null	This phase II trial is studying how well giving trastuzumab together with ixabepilone and carboplatin works in treating patients with HER2/neu-positive metastatic breast cancer. Monoclonal antibodies, such as trastuzumab, can locate tumor cells and either kill them or deliver tumor-killing substances to them without ha...	PRIMARY OBJECTIVES: I. To determine the response rate (as determined by RECIST criteria) to combination therapy with Ixabepilone (BMS-247550), trastuzumab, and carboplatin in patients with metastatic breast cancer known to overexpress HER2. SECONDARY OBJECTIVES: I. To determine time to disease progression (TTP) and ...	HER2-positive Breast Cancer Male Breast Cancer Recurrent Breast Cancer Stage IV Breast Cancer		null	1	arm 1: Induction therapy: Patients receive trastuzumab (Herceptin®) IV over 30 minutes\* on days 1, 8, 15, and 22 and ixabepilone IV over 1 hour and carboplatin IV over 1 hour on days 1, 8, and 15. Treatment repeats every 28 days for up to 6 courses in the absence of unacceptable toxicity. NOTE: \*Trastuzumab is given...	[ 0 ]	4	[ 2, 0, 0, 10 ]	intervention 1: Given IV intervention 2: Given IV intervention 3: Given IV intervention 4: Correlative studies	intervention 1: trastuzumab intervention 2: ixabepilone intervention 3: carboplatin intervention 4: laboratory biomarker analysis	1	Boston \| Massachusetts \| United States \| -71.05977 \| 42.35843	59	0	0	0	NCT00077376	1COMPLETED	2011-03-01	2005-03-01	National Cancer Institute (NCI)	0NIH	false	false	false	null	0	0	0	0	0
[ 3 ]	62	NA	SINGLE_GROUP	0TREATMENT	0NONE	false	0ALL	false	This phase II trial is studying how well giving rituximab together with combination chemotherapy and 90-Yttrium ibritumomab tiuxetan works in treating patients with stage I or stage II lymphoma. Drugs used in chemotherapy, such as prednisone, cyclophosphamide, doxorubicin, and vincristine, work in different ways to sto...	PRIMARY OBJECTIVES: I. To evaluate the complete response rate (CR) and functional CR rate in patients with previously untreated stage I (with at least 1 risk factor) or stage II CD20+ diffuse large cell lymphoma who receive therapy with R-CHOP followed by 90-Yttrium -Zevalin™. SECONDARY OBJECTIVES: I. To evaluate th...	Contiguous Stage II Adult Diffuse Large Cell Lymphoma Extranodal Marginal Zone B-cell Lymphoma of Mucosa-associated Lymphoid Tissue Nodal Marginal Zone B-cell Lymphoma Noncontiguous Stage II Adult Diffuse Large Cell Lymphoma Splenic Marginal Zone Lymphoma Stage I Adult Diffuse Large Cell Lymphoma Testicular Lymphoma Wa...		null	1	arm 1: R-CHOP (Rituximab, Cyclophosphamide, Doxorubicin, Vincristine, Prednisone): Patients receive R-CHOP every 21 days for 2 courses in the absence of disease progression or unacceptable toxicity. Patients achieving a complete response after 2 courses receive 2 additional courses. Patients achieving a partial respons...	[ 0 ]	8	[ 2, 0, 0, 0, 0, 4, 4, 3 ]	intervention 1: Given IV intervention 2: Given orally intervention 3: Given IV intervention 4: Given IV intervention 5: Given IV intervention 6: Given IV intervention 7: Undergo radiotherapy intervention 8: Undergo PET scans	intervention 1: rituximab intervention 2: prednisone intervention 3: cyclophosphamide intervention 4: doxorubicin intervention 5: vincristine intervention 6: indium In 111 ibritumomab tiuxetan intervention 7: radiation therapy intervention 8: positron emission tomography	1	Boston \| Massachusetts \| United States \| -71.05977 \| 42.35843	119	0	0	0	NCT00088881	6TERMINATED	2011-03-01	2004-12-01	National Cancer Institute (NCI)	0NIH	false	false	false	null	0	0	0	0	0
[ 3 ]	27	NA	SINGLE_GROUP	0TREATMENT	0NONE	false	0ALL	true	RATIONALE: Gefitinib may stop the growth of tumor cells by blocking the enzymes necessary for their growth. PURPOSE: Phase II trial to study the effectiveness of gefitinib in treating patients who have locally advanced or metastatic thyroid cancer that did not respond to iodine therapy.	OBJECTIVES: Primary * Determine the all-measurable-disease response rate in patients with iodine-refractory locally advanced or metastatic thyroid cancer treated with gefitinib. Secondary * Determine the toxicity of this drug in these patients. * Determine progression-free and overall survival of patients treated w...	Head and Neck Cancer	recurrent thyroid cancer stage III follicular thyroid cancer stage III papillary thyroid cancer stage IV follicular thyroid cancer stage IV papillary thyroid cancer anaplastic thyroid cancer thyroid gland medullary carcinoma	null	1	arm 1: None	[ 0 ]	1	[ 0 ]	intervention 1: Taken orally once a day for duration of benefit. Treatment is continuous until there is evidence of disease progression or unacceptable toxicity.	intervention 1: Gefitinib	2	Boston \| Massachusetts \| United States \| -71.05977 \| 42.35843 Boston \| Massachusetts \| United States \| -71.05977 \| 42.35843	27	0	0	0	NCT00095836	1COMPLETED	2011-03-01	2003-03-01	Massachusetts General Hospital	7OTHER	false	false	false	null	0	0	0	0	0
[ 3 ]	31	NA	SINGLE_GROUP	0TREATMENT	0NONE	false	1FEMALE	null	This phase II trial is studying how well lapatinib works in treating patients with recurrent or persistent endometrial cancer. Lapatinib may stop the growth of tumor cells by blocking the enzymes necessary for their growth	PRIMARY OBJECTIVES: I. Determine the 6-month progression-free survival of patients with recurrent or persistent endometrial carcinoma treated with lapatinib. II. Determine the nature and degree of toxicity of this drug in these patients. SECONDARY OBJECTIVES: I. Determine the objective response rate in patients tre...	Recurrent Endometrial Carcinoma		null	1	arm 1: Patients receive oral lapatinib once daily on days 1-28. Courses repeat every 28 days in the absence of disease progression or unacceptable toxicity.	[ 0 ]	1	[ 0 ]	intervention 1: None	intervention 1: lapatinib ditosylate	1	Philadelphia \| Pennsylvania \| United States \| -75.16362 \| 39.95238	30	0	0	0	NCT00096447	1COMPLETED	2011-03-01	2004-11-01	National Cancer Institute (NCI)	0NIH	false	false	false	null	0	0	0	0	0
[ 4 ]	255	RANDOMIZED	PARALLEL	0TREATMENT	0NONE	false	0ALL	true	This trial aims to compare the efficacy of oral prednisone vs. methylprednisolone injected into the middle ear for the treatment of moderate-to-severe, sudden sensorineural hearing loss (inner ear hearing loss affecting one ear that occurs over less than 72 hours).	Sudden deafness is believed to affect 1:5000 people yearly. The cause is unknown. Spontaneous improvement is seen in approximately 20% of subjects. Improvement is seen in approximately 60% of subjects treated promptly with oral corticosteroids. Anecdotal case reports and uncontrolled case series have suggested the intr...	Sudden Deafness	sudden hearing loss unilateral sudden sensorineural hearing loss sudden sensorineural hearing loss sudden unilateral hearing loss	null	2	arm 1: Nineteen days of oral prednisone arm 2: Four doses of methylprednisolone sodium succinate delivered by injection to the middle ear over 2 weeks	[ 5, 0 ]	2	[ 0, 0 ]	intervention 1: Oral, 19 days intervention 2: Four intratympanic injections delivered to the middle ear over 2 weeks	intervention 1: prednisone intervention 2: methylprednisolone sodium succinate	14	Los Angeles \| California \| United States \| -118.24368 \| 34.05223 San Diego \| California \| United States \| -117.16472 \| 32.71571 Gainesville \| Florida \| United States \| -82.32483 \| 29.65163 Iowa City \| Iowa \| United States \| -91.53017 \| 41.66113 Baltimore \| Maryland \| United States \| -76.61219 \| 39.29038 Boston \| Massac...	255	0	0	0	NCT00097448	1COMPLETED	2011-03-01	2004-12-01	Massachusetts Eye and Ear Infirmary	7OTHER	false	false	false	null	0	0	0	0	0
[ 3 ]	27	NON_RANDOMIZED	SINGLE_GROUP	0TREATMENT	0NONE	false	0ALL	true	Alemtuzumab is a man-made antibody used to treat certain blood disorders. Tacrolimus is a drug used to decrease immune system activity in people who have received organ transplants so that the new organ will not be rejected. This study will determine whether treatment with alemtuzumab and tacrolimus is effective in pre...	Organ transplantation is a common procedure in hospitals, but organ rejection and serious side effects are potential problems for the patient. Alemtuzumab is a monoclonal antibody that binds to and depletes excess T cells in the bone marrow of leukemia patients. In this study, alemtuzumab will destroy the recipient's w...	Liver Disease Liver Transplantation	transplantation liver transplant rejection tolerance antibody induction	null	1	arm 1: Liver transplant, with two in-patient infused doses of alemtuzumab; followed by maintenance immunotherapy with cyclosporine, mycophenolate mofetil, and/or tacrolimus; with possible immunosuppression withdrawal	[ 0 ]	6	[ 0, 0, 0, 0, 3, 3 ]	intervention 1: T-cell depleting monoclonal antibody; two doses by intravenous infusion on Days 0 and 4 intervention 2: Oral immunosuppressant intervention 3: Oral immunosuppressant intervention 4: Oral immunosuppressant intervention 5: Occurs at study entry intervention 6: Beginning no earlier than Year 1	intervention 1: Alemtuzumab intervention 2: Cyclosporine intervention 3: Mycophenolate mofetil intervention 4: Tacrolimus intervention 5: Liver transplant intervention 6: Immunosuppression withdrawal	9	San Francisco \| California \| United States \| -122.41942 \| 37.77493 Denver \| Colorado \| United States \| -104.9847 \| 39.73915 Miami \| Florida \| United States \| -80.19366 \| 25.77427 Ann Arbor \| Michigan \| United States \| -83.74088 \| 42.27756 Cleveland \| Ohio \| United States \| -81.69541 \| 41.4995 Philadelphia \| Pennsylvani...	27	0	0	0	NCT00105235	1COMPLETED	2011-03-01	2005-06-01	National Institute of Allergy and Infectious Diseases (NIAID)	0NIH	false	false	false	null	0	0	0	0	0
[ 3 ]	28	NA	SINGLE_GROUP	0TREATMENT	0NONE	false	1FEMALE	null	Lapatinib may stop the growth of tumor cells by blocking some of the enzymes needed for cell growth. This phase II trial is studying how well lapatinib works in treating patients with persistent or recurrent ovarian epithelial or peritoneal cancer.	OBJECTIVES: Primary I. Determine 6-month progression-free survival of patients with persistent or recurrent ovarian epithelial or primary peritoneal cancer treated with lapatinib. II. Determine the nature and degree of toxicity of this drug in these patients. Secondary I. Determine the clinical response rate (partial...	Primary Peritoneal Cavity Cancer Recurrent Ovarian Epithelial Cancer		null	1	arm 1: Patients receive oral lapatinib once daily on days 1-28. Courses repeat every 28 days in the absence of disease progression or unacceptable toxicity.	[ 0 ]	2	[ 0, 10 ]	intervention 1: Given orally intervention 2: Correlative studies	intervention 1: lapatinib ditosylate intervention 2: laboratory biomarker analysis	1	Philadelphia \| Pennsylvania \| United States \| -75.16362 \| 39.95238	25	0	0	0	NCT00113373	1COMPLETED	2011-03-01	2005-05-01	National Cancer Institute (NCI)	0NIH	false	false	false	null	0	0	0	0	0
[ 4 ]	167	RANDOMIZED	PARALLEL	0TREATMENT	0NONE	false	0ALL	true	This trial compares the safety and effectiveness of catheter ablation for PAF with antiarrhythmic drug therapy. The investigational catheter being studied is the NAVISTAR® THERMOCOOL® irrigated-tip catheter. At the time of this study, the NAVISTAR® THERMOCOOL® catheter was FDA-approved for commercial distribution in th...	null	Heart Diseases Arrhythmia Atrial Fibrillation	Atrial Fibrillation Paroxysmal Atrial Fibrillation	null	2	arm 1: None arm 2: None	[ 0, 1 ]	2	[ 1, 0 ]	intervention 1: The Biosense Webster NAVISTAR® THERMOCOOL® Diagnostic/Ablation Deflectable Tip Catheter is a luminal catheter with a deflectable tip designed to facilitate electrophysiological mapping of the heart and to transmit radiofrequency current to the catheter tip electrode for ablation purposes. intervention 2...	intervention 1: NAVISTAR® THERMOCOOL® Catheter intervention 2: Antiarrhythmic drug	17	Greenbrae \| California \| United States \| -122.5247 \| 37.94854 Orlando \| Florida \| United States \| -81.37924 \| 28.53834 Maywood \| Illinois \| United States \| -87.84312 \| 41.8792 Baltimore \| Maryland \| United States \| -76.61219 \| 39.29038 Burlington \| Massachusetts \| United States \| -71.19561 \| 42.50482 New York \| New Yor...	164	0	0	0	NCT00116428	1COMPLETED	2011-03-01	2004-10-01	Biosense Webster, Inc.	4INDUSTRY	false	false	false	null	0	0	0	0	0
[ 3 ]	257	RANDOMIZED	PARALLEL	0TREATMENT	0NONE	false	1FEMALE	false	An open-label randomized Phase II study in order to explore two different sequential anthracycline-based neoadjuvant treatment regimens in female patients with primary, operable breast cancer (T2-T4/N0-2/M0).	null	Breast Cancer		null	2	arm 1: None arm 2: None	[ 0, 1 ]	4	[ 0, 0, 0, 0 ]	intervention 1: 500 mg/m\^2, intravenous (IV), every 21 days, 4 cycles (1-4) intervention 2: 600 mg/m2, intravenous (IV), every 21 days, 4 cycles (1-4) intervention 3: 60 mg/m\^2, intravenous (IV), every 21 days, 4 cycles (1-4) intervention 4: 100 mg/m\^2, intravenous (IV), every 21 days, 4 cycles (5-8)	intervention 1: pemetrexed intervention 2: cyclophosphamide intervention 3: doxorubicin intervention 4: docetaxel	11	Baden-Baden \| N/A \| Germany \| 8.23975 \| 48.7606 Berlin \| N/A \| Germany \| 13.41053 \| 52.52437 Hamburg \| N/A \| Germany \| 9.99302 \| 53.55073 Heidelberg \| N/A \| Germany \| 8.69079 \| 49.40768 Cremona \| N/A \| Italy \| 10.02129 \| 45.13325 Rozzano \| N/A \| Italy \| 9.1559 \| 45.38193 Moscow \| N/A \| Russia \| 37.61556 \| 55.75222 Sain...	257	0	0	0	NCT00149214	1COMPLETED	2011-03-01	2005-09-01	Eli Lilly and Company	4INDUSTRY	false	false	false	null	0	0	0	0	0
[ 4 ]	263	RANDOMIZED	PARALLEL	0TREATMENT	0NONE	false	1FEMALE	null	Estrogen is known to be a regulator of bone and lipid metabolism. Letrozole is a potent inhibitor of estrogen synthesis. This study evaluated the effects of letrozole and tamoxifen on bone and lipid metabolism in postmenopausal women with resected, receptor positive early breast cancer.	null	Hormone Sensitive Resected Primary Breast Cancer in Postmenopausal Women	Breast Cancer Letrozole Bone Mineral Density Bone Markers Serum lipid Postmenopausal	null	2	arm 1: 2.5 mg once daily (q.d.)orally for 5 years arm 2: 20 mg Tamoxifen once daily (q.d.) orally for 2 years followed by Letrozole 2.5 mg q.d. orally for 3 years.	[ 0, 0 ]	2	[ 0, 0 ]	intervention 1: 2.5 mg tablets and supplied in bottles with 6-monthly supplies. intervention 2: 20 mg tablets in bottles as 6-monthly supplies (supplied to Novartis as Tamofen from Schering Oy, Subsidiary of Schering AG, Pansiontie 47, FIN-2010 Turku, Finland)	intervention 1: Letrozole intervention 2: Tamoxifen	13	Aalborg \| N/A \| Denmark \| 9.9187 \| 57.048 Aarhus \| N/A \| Denmark \| 10.21076 \| 56.15674 Copenhagen \| N/A \| Denmark \| 12.56553 \| 55.67594 Esbjerg \| N/A \| Denmark \| 8.45187 \| 55.47028 Herlev \| N/A \| Denmark \| 12.43998 \| 55.72366 Herning \| N/A \| Denmark \| 8.97662 \| 56.13615 Hillerød \| N/A \| Denmark \| 12.30081 \| 55.92791 Kl...	263	0	0	0	NCT00171704	1COMPLETED	2011-03-01	2005-04-01	Novartis Pharmaceuticals	4INDUSTRY	false	false	false	null	0	0	0	0	0
[ 5 ]	31	RANDOMIZED	PARALLEL	0TREATMENT	2DOUBLE	false	0ALL	false	Staphylococcus aureus (S. aureus) infection is perceived not only as a common secondary complication of atopic dermatitis (AD), but also as a culprit in the worsening of this condition. In addition, the recent development of community acquired methicillin-resistant S. aureus (CA-MRSA) has presented a new challenge to o...	Background Atopic dermatitis (AD) is a chronic condition of pruritus and eczematous lesions that affects 15-20% of children. It commonly presents early in life and is associated with other atopic diseases. Pathogenesis is multifactorial with genetic, immunologic, and environmental components. Generally, decreased produ...	Atopic Dermatitis		null	2	arm 1: Intranasal mupirocin ointment and sodium hypochlorite (bleach) baths arm 2: Intranasal petrolatum ointment treatment and plain water baths	[ 1, 2 ]	4	[ 0, 0, 0, 0 ]	intervention 1: Sodium hypochlorite (bleach) baths twice weekly for 3 months intervention 2: Intranasal mupirocin 2% ointment BID x five days (3 times total for subjects; one time only for family members) intervention 3: Water baths twice weekly for three months intervention 4: Intranasal petrolatum ointment twice dail...	intervention 1: Sodium hypochlorite (bleach) baths intervention 2: Mupirocin ointment intervention 3: Water intervention 4: Petrolatum Ointment	1	Chicago \| Illinois \| United States \| -87.65005 \| 41.85003	31	0	0	0	NCT00179959	1COMPLETED	2011-03-01	2005-09-01	Northwestern University	7OTHER	false	false	false	null	0	0	0	0	0
[ 3 ]	66	NA	SINGLE_GROUP	0TREATMENT	0NONE	false	0ALL	true	The patients eligible for this study are those diagnosed with glioblastoma or gliosarcoma who have recently undergone surgery and who have not been treated with radiation therapy or chemotherapy. This is called a phase II study. The purpose of the phase II study is to determine how effective Tarceva plus Temodar plus r...	This is a Phase II Study of Tarceva plus Temodar during and following radiation therapy in patients with newly diagnosed glioblastoma multiforme and gliosarcoma. The efficacy and safety profile of Tarceva in combination with radiation therapy plus Temodar will be studied. In addition, correlations between response to t...	Glioblastoma Multiforme Gliosarcoma	Glioblastoma Multiforme Gliosarcoma GBM GS Tarceva Temodar Radiation Newly Diagnosed	null	1	arm 1: Single arm phase-2 experimental treatment of newly diagnosed patients with Glioblastoma with Temodar plus Tarceva plus Radiation Therapy	[ 0 ]	3	[ 0, 0, 3 ]	intervention 1: Tarceva (erlotinib hydrochloride; previously referred to as OSI-774), a quinazoline, is an orally active, potent, selective inhibitor of EGFR tyrosine kinase. 100 - 300 milligrams (mg) every day (QD) orally (PO) every (q) 28 days depending on EIAED Status intervention 2: Temodar 200 mg/m\^2/day x 5 days...	intervention 1: Tarceva intervention 2: Temodar intervention 3: Radiation Therapy	1	San Francisco \| California \| United States \| -122.41942 \| 37.77493	66	0	0	0	NCT00187486	1COMPLETED	2011-03-01	2004-08-01	University of California, San Francisco	7OTHER	false	false	false	null	0	0	0	0	0
[ 3 ]	45	NA	SINGLE_GROUP	0TREATMENT	0NONE	false	0ALL	true	The purpose of this study is to evaluate the safety and effectiveness of the bevacizumab and capecitabine combination in frail patients with untreated metastatic colorectal cancer.	The study will evaluate the tolerability, safety, and feasibility of combination bevacizumab and capecitabine in a small number of frail patients with metastatic colorectal cancer who have a compromised performance status. Preclinical studies suggest that the combination of chemotherapy and anti-angiogenic therapy offe...	Colorectal Cancer		null	1	arm 1: Bevacizumab 7.5 mg/kg every 3 weeks will be administered interavenously (IV) to the enrolled patients. Oral capecitabine 1000 mg/m\^2 twice daily for 14 days followed by 7 days off every 21 days. Treatment will continue until disease progression, unacceptable toxicity, or withdrawal of patient consent.	[ 0 ]	2	[ 0, 0 ]	intervention 1: 1000mg/m\^2 administered orally twice daily for two weeks followed by one week rest period intervention 2: 7.5 mg/kg IV will be administered every 3 weeks	intervention 1: Capecitabine (Xeloda) intervention 2: Bevacizumab	12	Alhambra \| California \| United States \| -118.12701 \| 34.09529 Bakersfield \| California \| United States \| -119.01871 \| 35.37329 Fullerton \| California \| United States \| -117.92534 \| 33.87029 Long Beach \| California \| United States \| -118.18923 \| 33.76696 Los Angeles \| California \| United States \| -118.24368 \| 34.05223 N...	45	0	0	0	NCT00203411	1COMPLETED	2011-03-01	2006-03-01	Translational Oncology Research International	7OTHER	false	false	false	null	0	0	0	0	0
[ 3 ]	7	NA	SINGLE_GROUP	0TREATMENT	0NONE	false	0ALL	false	This trial is the follow-on trial to a preceeding open-label trial which included patients with chronic refractory neuropathic pain. It is conducted at one site in the United Kingdom and the patient enrollment is completed. The patients had successfully completed the above mentioned trial and, in the investigator's opi...	null	Chronic Refractory Neuropathic Pain		null	1	arm 1: Open-label active treatment	[ 0 ]	1	[ 0 ]	intervention 1: Dosage: Lacosamide up to 400 mg/day; Dosage form: Film-coated tablets; Dosage Frequency and Duration: Two times per day; 9.5 years	intervention 1: Lacosamide	1	Monheim \| N/A \| Germany \| 10.85834 \| 48.84389	7	0	0	0	NCT00237458	1COMPLETED	2011-03-01	2001-05-01	UCB Pharma	4INDUSTRY	false	false	false	null	0	0	0	0	0
[ 3 ]	12	RANDOMIZED	PARALLEL	0TREATMENT	0NONE	false	0ALL	true	RATIONALE: Giving the herb Boswellia serrata after surgery and radiation therapy may slow the growth of any remaining tumor cells. It is not yet known whether giving Boswellia serrata together with standard treatment is more effective than standard treatment alone in treating high-grade gliomas. PURPOSE: This randomiz...	OBJECTIVES: Primary * To determine whether a herbal approach to decreasing 5-LO eicosanoid production reduces peritumoral brain edema in patients with HGG. Secondary * To determine if this adjuvant approach improves the quality of life and progression free and overall survival of patients with HGG. OUTLINE: This a...	Brain and Central Nervous System Tumors Cerebral Edema	cerebral edema adult glioblastoma adult giant cell glioblastoma adult gliosarcoma adult anaplastic astrocytoma adult anaplastic oligodendroglioma	null	2	arm 1: Patients receive oral Boswellia serrata extract 4 times a day and oral cyanocobalamin (vitamin B 12) once a day for 6 months in the absence of unacceptable toxicity. arm 2: Patients in the control arm receive oral cyanocobalamin (vitamin B 12) once a day for 6 months.	[ 0, 1 ]	2	[ 0, 7 ]	intervention 1: given orally intervention 2: given orally	intervention 1: Boswellia serrata extract intervention 2: cyanocobalamin	1	Cleveland \| Ohio \| United States \| -81.69541 \| 41.4995	12	0	0	0	NCT00243022	6TERMINATED	2011-03-01	2004-09-01	Ali Altunkaya	7OTHER	false	false	false	null	0	0	0	0	0
[ 3 ]	2	RANDOMIZED	PARALLEL	0TREATMENT	3TRIPLE	false	0ALL	true	This is a pilot study intended to find out if 3,4-methylenedioxymethamphetamine (MDMA) is safe and can help people with advanced stage cancer and anxiety arising from the cancer diagnosis.	People who learn they have cancer can feel frightened, upset and depressed, and a diagnosis of advanced stage cancer can generate intense anxiety. People with advanced stage cancer may be anxious about their deteriorating health and the nearness of death, disruption in their close relationships caused by current or fut...	Anxiety Disorder Cancer	MDMA cancer anxiety psychotherapy quality of life	null	3	arm 1: 8 subjects will receive full or nearly full doses of MDMA in Stage 1 and do not continue to participate into Stage 2. arm 2: 4 individuals will receive sub-threshold to threshold minimal doses of MDMA in Stage I arm 3: The 4 subjects assigned in Stage I to the control arm will have the option to continue into St...	[ 0, 1, 0 ]	4	[ 0, 0, 5, 0 ]	intervention 1: Dosage form: capsule Dosage frequency and duration for the treatment arm (8 subjects in Stage 1 and the other 4 subjects in Stage 1 who may continue into Stage 2): Session 1: 83.3mg followed 2.5 hours later with optional 41.7 mg for total of 125mg Session 2 (two to three weeks later): 125mg followed 2...	intervention 1: Stage 1 Active Methylenedioxymethamphetamine intervention 2: Stage 1 Low dose Methylenedioxymethamphetamine intervention 3: Psychotherapy intervention 4: Stage 2 Active Methylenedioxymethamphetamine	1	Belmont \| Massachusetts \| United States \| -71.17867 \| 42.39593	2	0	0	0	NCT00252174	6TERMINATED	2011-03-01	2007-02-01	Brigham and Women's Hospital	7OTHER	false	false	false	null	0	0	0	0	0
[ 3 ]	47	NA	SINGLE_GROUP	0TREATMENT	0NONE	false	0ALL	false	The presence of c-kit mutation is an independent poor prognostic factor for relapse in addition to large size (\> 5 cm) and high mitotic rate (\> 5/50 high power field \[HPF\]) in localized gastrointestinal stromal tumor (GIST) patients who underwent complete surgical resection. In addition, the localized GIST which ha...	null	Sarcoma Gastrointestinal Stromal Tumors	GIST Imatinib Adjuvant therapy Kit mutation	null	1	arm 1: patients receiving adjuvant imatinib mesylate	[ 0 ]	1	[ 0 ]	intervention 1: Imatinib mesylate 400mg/day per oral (day 1-28) every 4 weeks	intervention 1: Imatinib mesylate (Glivec)	4	Goyang \| N/A \| South Korea \| 127.19731 \| 36.21689 Seoul \| N/A \| South Korea \| 126.9784 \| 37.566 Seoul \| N/A \| South Korea \| 126.9784 \| 37.566 Seoul \| N/A \| South Korea \| 126.9784 \| 37.566	47	0	0	0	NCT00278876	1COMPLETED	2011-03-01	2005-04-01	Asan Medical Center	7OTHER	false	false	false	null	0	0	0	0	0
[ 3 ]	208	RANDOMIZED	PARALLEL	0TREATMENT	0NONE	false	1FEMALE	false	This is a multi-center, open-label, randomized Phase II study in previously untreated patients with metastatic breast cancer to evaluate the antitumor activity and safety of weekly dose-dense ABI-007 (Abraxane) compared to 2-weekly regimen vs the standard 3-weekly infusion. All patients will also receive concurrent bev...	null	Breast Neoplasms Neoplasm Metastasis	First Line Metastatic Breast Cancer	null	3	arm 1: 260 mg/m\^2 every 3 weeks and 15 mg/kg bevacizumab every 3 weeks arm 2: 260 mg/m\^2 ABI-007 every 2 weeks and 10 mg/kg bevacizumab every 2 weeks arm 3: 130 mg/m\^2 ABI-007 weekly (without a week of 'rest') and 10 mg/kg bevacizumab every 2 weeks	[ 0, 0, 0 ]	2	[ 0, 0 ]	intervention 1: 30 minute infusions intervention 2: infusions	intervention 1: ABI-007 (Abraxane) intervention 2: bevacizumab	40	Birmingham \| Alabama \| United States \| -86.80249 \| 33.52066 Little Rock \| Arkansas \| United States \| -92.28959 \| 34.74648 Fresno \| California \| United States \| -119.77237 \| 36.74773 Glendale \| California \| United States \| -118.25508 \| 34.14251 Fort Collins \| Colorado \| United States \| -105.08442 \| 40.58526 Bridgeport \|...	208	0	0	0	NCT00281528	6TERMINATED	2011-03-01	2006-02-01	Celgene	4INDUSTRY	false	false	false	null	0	0	0	0	0
[ 3 ]	20	RANDOMIZED	PARALLEL	0TREATMENT	2DOUBLE	false	0ALL	null	Pemphigus vulgaris (PV) is a rare skin disorder that causes blistering of the skin and mucous membranes. Infliximab is a man-made antibody used to treat certain types of immune system disorders, including rheumatoid arthritis and Crohn's disease. This study will determine if infliximab given in combination with prednis...	PV involves blistering of the outer layer of skin and mucous membranes, causing a separation of epidermal cells. The disease occurs when the immune system produces antibodies to specific proteins in the skin and mucous membranes; the cause for production of these autoantibodies is unknown. Infliximab is a genetically e...	Pemphigus	Skin Diseases Autoimmune Diseases	null	2	arm 1: Participants are randomized to receive intravenous infusions of infliximab (5mg/kg reconstituted in 10 mL of Sterile Water for Injection, USP ) at Weeks 0, 2, 6, and 14 over a time period of no less than two hours in a masked (blinded) fashion. Refer to section titled, "Detailed Description" for additional treat...	[ 0, 2 ]	2	[ 0, 10 ]	intervention 1: Chimeric IgG monoclonal antibody that binds to TNF-alpha, generally used to treat Crohn's disease, given in a dosage of 5 mg/kg intervention 2: Placebo administered in place of infliximab for control group	intervention 1: Infliximab intervention 2: Placebo Comparator	4	Los Angeles \| California \| United States \| -118.24368 \| 34.05223 Iowa City \| Iowa \| United States \| -91.53017 \| 41.66113 Durham \| North Carolina \| United States \| -78.89862 \| 35.99403 Philadelphia \| Pennsylvania \| United States \| -75.16362 \| 39.95238	20	0	0	0	NCT00283712	1COMPLETED	2011-03-01	2006-03-01	National Institute of Allergy and Infectious Diseases (NIAID)	0NIH	false	false	false	null	0	0	0	0	0
[ 2, 3 ]	50	NON_RANDOMIZED	SINGLE_GROUP	0TREATMENT	0NONE	false	0ALL	true	RATIONALE: Giving chemotherapy, such as fludarabine phosphate and cyclophosphamide, and total body irradiation, before peripheral blood stem cell transplant helps stop the growth of cancer cells. It may also stop the patient's immune system from rejecting the donor's stem cells. When the healthy stem cells and natural ...	OBJECTIVES: Primary * To determine the disease-free survival at 6 months and 1 year in patients with high-risk myeloid malignancies who undergo a reduced-intensity haploidentical hematopoietic stem cell transplantation (HSCT) supplemented with donor natural killer (NK) cells. Secondary * To evaluate the in vivo exp...	Acute Myelogenous Leukemia	NK cells natural killer cells immunotherapy hematopoietic cell transplant acute myelogenous leukemia	null	2	arm 1: Patients with high risk myeloid malignancies undergoing allogeneic hematopoietic stem cell transplantation, receiving fludarabine phosphate (daily dose of 40mg/m\^2), cyclophosphamide (administered on Day -15 only), cyclosporin A, total body irradiation, natural killer cells, aldesleukin, and thymoglobulin. arm ...	[ 0, 0 ]	10	[ 2, 2, 0, 0, 3, 4, 2, 0, 0, 0 ]	intervention 1: Administered subcutaneously (SQ) 9 million units every other day beginning Day -12 through -2 (evening of natural killer cell infusion) for a total of 6 doses. intervention 2: Infusion given on Day -12; The targeted infused cell dose of CD3- CD19- selected NK product is within the range of 2-3 x 10\^7 c...	intervention 1: aldesleukin intervention 2: natural killer cells intervention 3: cyclophosphamide intervention 4: fludarabine phosphate intervention 5: allogeneic hematopoietic stem cell transplantation intervention 6: total body irradiation intervention 7: Thymoglobulin intervention 8: Cyclosporin A intervention 9: cy...	1	Minneapolis \| Minnesota \| United States \| -93.26384 \| 44.97997	47	0	0	0	NCT00303667	1COMPLETED	2011-03-01	2005-01-01	Masonic Cancer Center, University of Minnesota	7OTHER	false	false	false	null	0	0	0	0	0
[ 3 ]	10	NA	SINGLE_GROUP	0TREATMENT	0NONE	false	0ALL	null	This phase II trial is studying how well AZD2171 works in treating patients with refractory metastatic kidney cancer. AZD2171 may stop the growth of tumor cells by blocking some of the enzymes needed for cell growth and by blocking blood flow to the tumor.	PRIMARY OBJECTIVES: I. Determine the objective response rate in patients with refractory metastatic renal cell carcinoma treated with AZD2171. SECONDARY OBJECTIVES: I. Determine the safety and tolerability of AZD2171 in these patients. II. Determine the feasibility of performing standardized delayed contrast-enhance...	Clear Cell Renal Cell Carcinoma Recurrent Renal Cell Cancer Stage IV Renal Cell Cancer		null	1	arm 1: Patients receive oral AZD2171 once daily for 4 weeks. Treatment repeats every 4 weeks in the absence of disease progression or unacceptable toxicity.	[ 0 ]	2	[ 0, 10 ]	intervention 1: Given orally intervention 2: Correlative studies	intervention 1: cediranib maleate intervention 2: laboratory biomarker analysis	1	Chicago \| Illinois \| United States \| -87.65005 \| 41.85003	10	0	0	0	NCT00303862	6TERMINATED	2011-03-01	2006-03-01	National Cancer Institute (NCI)	0NIH	false	false	false	null	0	0	0	0	0
[ 3 ]	80	NA	SINGLE_GROUP	0TREATMENT	0NONE	false	0ALL	false	This phase II trial will evaluate the combination of bevacizumab + RAD001 in patients with metastatic renal cell carcinoma. In this trial the investigators will evaluate this combination in patients previously untreated with any anti-angiogenesis agent and patients who have previously received one prior regimen contain...	All eligible patients will receive: * Bevacizumab 10mg/kg, IV infusion, every 2 weeks * RAD001 10 mg by mouth daily All patients will be evaluated for response after completing two courses (8 weeks) of treatment. Patients with objective tumor response or stable disease will continue treatment with bevacizumab adn RAD...	Kidney Cancer	kidney cancer bevacizumab	null	1	arm 1: Bevacizumab 10mg/kg, IV infusion, every 2 weeks RAD001 10 mg by mouth daily	[ 0 ]	2	[ 0, 0 ]	intervention 1: Bevacizumab 10mg/kg, IV infusion, every 2 weeks intervention 2: RAD001 10 mg by mouth daily	intervention 1: bevacizumab intervention 2: RAD001	12	Fort Myers \| Florida \| United States \| -81.84059 \| 26.62168 Gainesville \| Florida \| United States \| -82.32483 \| 29.65163 Jacksonville \| Florida \| United States \| -81.65565 \| 30.33218 Orlando \| Florida \| United States \| -81.37924 \| 28.53834 Marietta \| Georgia \| United States \| -84.54993 \| 33.9526 Louisville \| Kentucky \|...	80	0	0	0	NCT00323739	1COMPLETED	2011-03-01	2006-05-01	SCRI Development Innovations, LLC	7OTHER	false	false	false	null	0	0	0	0	0
[ 3 ]	34	NON_RANDOMIZED	SINGLE_GROUP	0TREATMENT	0NONE	false	1FEMALE	true	RATIONALE: Dose-dense scheduling with (peg)filgrastim support may improve the clinical and pathologic complete response rate (pCR) and safety profile of single agent neoadjuvant docetaxel therapy. PURPOSE: To evaluate whether dose-dense scheduling with (peg)filgrastim support may improve the clinical and pathologic co...	OBJECTIVES: Primary * Pathologic complete response rate (pCR) of dose dense docetaxel in the neoadjuvant setting. Secondary * Safety and toxic effects of this regimen in these patients. * Tumor response rate (as measured by ultrasound) in patients treated with this regimen. * Determine whether early changes in mark...	Breast Cancer	inflammatory breast cancer stage II breast cancer stage IIIA breast cancer stage IIIB breast cancer stage IIIC breast cancer	null	1	arm 1: None	[ 0 ]	6	[ 0, 6, 10, 3, 3, 3 ]	intervention 1: Docetaxel 75 mg/m2 IV (1-hour infusion) on day 1 of each cycle (cycle = 2 weeks) x 4 cycles intervention 2: protein expression analysis intervention 3: laboratory biomarker analysis intervention 4: biopsy intervention 5: conventional surgery intervention 6: neoadjuvant therapy	intervention 1: docetaxel intervention 2: protein expression analysis intervention 3: laboratory biomarker analysis intervention 4: biopsy intervention 5: conventional surgery intervention 6: neoadjuvant therapy	2	Nashville \| Tennessee \| United States \| -86.78444 \| 36.16589 Nashville \| Tennessee \| United States \| -86.78444 \| 36.16589	32	0	0	0	NCT00343512	6TERMINATED	2011-03-01	2004-02-01	Vanderbilt-Ingram Cancer Center	7OTHER	false	false	false	null	0	0	0	0	0
[ 3 ]	49	NON_RANDOMIZED	SINGLE_GROUP	0TREATMENT	0NONE	false	0ALL	false	Objectives: 1. To estimate progression-free survival (PFS) at 12 months in subjects with metastatic colorectal cancer who receive FOLFIRI \[folinic acid (leucovorin or LV), 5-Fluorouracil (5-FU), irinotecan) plus bevacizumab as first line treatment. 2. To determine the objective response rate and the duration of objec...	Colorectal cancer growth may be affected by a protein in the body called "vascular endothelial growth factor" (VEGF). A drug that blocks VEGF may be an effective treatment for colorectal cancer. Bevacizumab is designed to block VEGF. Bevacizumab will be added to 5-Fluorouracil (5-FU), leucovorin (LV), and irinotecan, a...	Colorectal Cancer	Colorectal Cancer FOLFIRI Irinotecan CPT-11 Leucovorin LV Folinic Acid Fluorouracil 5-FU Adrucil Efudex Bevacizumab Avastin Anti-VEGF monoclonal antibody rhuMAb-VEGF	null	1	arm 1: FOLFIRI \[folinic acid (leucovorin) 400 mg/m\^2 by vein (IV) Day 1; 5-FU 400 mg/m\^2 IV injection Day 1 immediately followed by 2.4 g/m\^2 IV over 46 hours over Days 1-3; Irinotecan 180 mg/m\^2 IV on Day 1\] + Bevacizumab 5 mg/kg over 90 minutes on Day 1 administered alone then 5 mg/kg IV on Day 1 of 14 day cycl...	[ 0 ]	4	[ 0, 0, 0, 0 ]	intervention 1: 400 mg/m\^2 injection by vein Day 1 of 14 day cycle immediately after completion of leucovorin infusion. 2.4 g/m\^2 by vein over 46 hours over Days 1-3 of 14 day cycle immediately after completion of 400 mg/m\^2 injection. intervention 2: 5 mg/kg over 90 minutes on Day 1 of first 14 day cycle as initia...	intervention 1: 5-Fluorouracil intervention 2: Bevacizumab intervention 3: Leucovorin intervention 4: Irinotecan	2	Houston \| Texas \| United States \| -95.36327 \| 29.76328 Houston \| Texas \| United States \| -95.36327 \| 29.76328	43	0	0	0	NCT00354978	1COMPLETED	2011-03-01	2005-01-01	M.D. Anderson Cancer Center	7OTHER	false	false	false	null	0	0	0	0	0
[ 4 ]	1,029	RANDOMIZED	PARALLEL	0TREATMENT	0NONE	false	0ALL	false	This study assesses the effects of twice-daily subcutaneous injection exenatide versus treatment with sulfonylurea (glimepiride) on long-term glycemic control and beta-cell function.	null	Type 2 Diabetes Mellitus	exenatide diabetes Amylin Lilly glimepiride	null	2	arm 1: None arm 2: None	[ 0, 1 ]	2	[ 0, 0 ]	intervention 1: subcutaneous injection (5mcg or 10mcg), twice a day intervention 2: oral tablet (titrated to maximally tolerated dose), once daily	intervention 1: exenatide intervention 2: glimepiride	114	Graz \| N/A \| Austria \| 15.45 \| 47.06667 Innsbruck \| N/A \| Austria \| 11.39454 \| 47.26266 Salzburg \| N/A \| Austria \| 13.04399 \| 47.79941 Vienna \| N/A \| Austria \| 16.37208 \| 48.20849 Beroun \| N/A \| Czechia \| 14.072 \| 49.96382 České Budějovice \| N/A \| Czechia \| 14.47434 \| 48.97447 Hradec Králové \| N/A \| Czechia \| 15.83277 ...	1,335	0	0	0	NCT00359762	1COMPLETED	2011-03-01	2006-09-01	AstraZeneca	4INDUSTRY	false	false	false	null	0	0	0	0	0
[ 3 ]	32	NA	SINGLE_GROUP	0TREATMENT	0NONE	false	0ALL	false	The current study is being conducted to evaluate the possibility that a different schedule of bortezomib, doxorubicin HCl liposome, and dexamethasone might decrease the incidence of peripheral neuropathy yet maintain similar efficacy and allow maintenance of bortezomib dosing for a longer period.	null	Multiple Myeloma	Relapsed Multiple Myeloma Refractory Multiple Myeloma	null	0	null	null	3	[ 0, 0, 0 ]	intervention 1: Patients will be treated with bortezomib at 1.3mg/m\^2 on Days 1, 4, 15, and 18 every 28 days (cycle). intervention 2: Dexamethasone tablets will be given at 20mg daily on Days 1, 2, 4, 5, 15, 16, 18, and 19 every 28 days (cycle). intervention 3: Patients will receive intravenous doxorubicin HCl liposom...	intervention 1: bortezomib intervention 2: dexamethasone intervention 3: doxorubicin HCl liposome	15	La Verne \| California \| United States \| -117.76784 \| 34.10084 Waterbury \| Connecticut \| United States \| -73.0515 \| 41.55815 Miami \| Florida \| United States \| -80.19366 \| 25.77427 Athens \| Georgia \| United States \| -83.37794 \| 33.96095 Augusta \| Georgia \| United States \| -81.97484 \| 33.47097 Marietta \| Georgia \| United ...	32	0	0	0	NCT00366106	6TERMINATED	2011-03-01	2006-07-01	Accelerated Community Oncology Research Network	7OTHER	false	false	false	null	0	0	0	0	0
[ 5 ]	131	NON_RANDOMIZED	SINGLE_GROUP	0TREATMENT	0NONE	false	0ALL	false	The purpose of this clinical research study is to develop observational clinical experience with the use of entecavir in participants who are either of Black/African-American race or of Hispanic ethnicity.	null	Hepatitis B Infection		null	1	arm 1: None	[ 0 ]	1	[ 0 ]	intervention 1: Tablets, Oral, 0.5 mg, once daily, up to 52 weeks	intervention 1: Entecavir	27	Montgomery \| Alabama \| United States \| -86.29997 \| 32.36681 Tucson \| Arizona \| United States \| -110.92648 \| 32.22174 Washington D.C. \| District of Columbia \| United States \| -77.03637 \| 38.89511 Miami \| Florida \| United States \| -80.19366 \| 25.77427 Miami \| Florida \| United States \| -80.19366 \| 25.77427 Chicago \| Illin...	46	0	0	0	NCT00371150	1COMPLETED	2011-03-01	2006-11-01	Bristol-Myers Squibb	4INDUSTRY	false	false	false	null	0	0	0	0	0
[ 3 ]	35	NA	SINGLE_GROUP	0TREATMENT	0NONE	false	0ALL	false	This phase II trial is studying how well giving 3-AP together with fludarabine works in treating patients with myeloproliferative disorders (MPD), chronic myelomonocytic leukemia (CMML), or accelerated phase or blastic phase chronic myelogenous leukemia. Drugs used in chemotherapy, such as 3-AP and fludarabine, work in...	OBJECTIVES: I. Determine the efficacy of 3-AP (Triapine®) followed by fludarabine phosphate in patients with myeloproliferative disorders or chronic myelomonocytic leukemia in aggressive phase or transformation or chronic myelogenous leukemia in accelerated phase or blast crisis. II. Determine the toxicity of this re...	Accelerated Phase Chronic Myelogenous Leukemia Atypical Chronic Myeloid Leukemia, BCR-ABL1 Negative Blastic Phase Chronic Myelogenous Leukemia Chronic Eosinophilic Leukemia Chronic Myelomonocytic Leukemia Essential Thrombocythemia Philadelphia Chromosome Negative Chronic Myelogenous Leukemia Polycythemia Vera Primary M...		null	1	arm 1: Patients receive 3-AP (Triapine®) IV over 4 hours followed by fludarabine phosphate IV over 30 minutes on days 1-5. Courses repeat every 21 days in the absence of disease progression or unacceptable toxicity.	[ 0 ]	3	[ 0, 0, 3 ]	intervention 1: Given IV intervention 2: Given IV intervention 3: Correlative study	intervention 1: fludarabine phosphate intervention 2: triapine intervention 3: laboratory biomarker analysis	1	Baltimore \| Maryland \| United States \| -76.61219 \| 39.29038	35	0	0	0	NCT00381550	1COMPLETED	2011-03-01	2006-08-01	National Cancer Institute (NCI)	0NIH	false	false	false	null	0	0	0	0	0
[ 2, 3 ]	26	NA	SINGLE_GROUP	0TREATMENT	0NONE	false	0ALL	false	The purpose of this study is to evaluate the effectiveness of oral topotecan and how well the chemotherapy is tolerated (any side effects) when it is given in different dose levels. The study will also collect information on how the medication is being broken down and absorbed in the body and how quality of life is aff...	null	Tumors	Solid Tumors	null	0	null	null	1	[ 0 ]	intervention 1: Topotecan will be received in one of the five dose levels:0.25mg/day,0.5mg/day, 0.75mg/day, 1.0mg/day, and 1.25mg/day.	intervention 1: Oral Topotecan	1	Memphis \| Tennessee \| United States \| -90.04898 \| 35.14953	26	0	0	0	NCT00382733	1COMPLETED	2011-03-01	2006-11-01	Accelerated Community Oncology Research Network	7OTHER	false	false	false	null	0	0	0	0	0
[ 3 ]	21	NA	SINGLE_GROUP	0TREATMENT	0NONE	false	1FEMALE	true	This trial combines dose dense chemotherapy with doxorubicin and cyclophosphamide (AC) followed by standard, every 3 week docetaxel and GW572016 (lapatinib) for neoadjuvant treatment of Her2neu positive stage II/III breast cancer. The purpose of the study was to determine whether lapatinib combined with chemotherapy wa...	Lapatinib acts as a dual inhibitor of both epidermal growth factor receptor (EGFR) and ErbB-2 (Her2/neu) tyrosine kinase activity. EGFR and ErbB2 receptors are frequently over-expressed or altered in human cancers including breast cancer. This study plans to determine the antitumor activity of this regimen and its effe...	Breast Cancer Metastatic Breast Cancer		null	1	arm 1: Doxorubicin (Adriamycin) + cyclophosphamide (Cytoxan) with pegfilgrastim or filgrastim growth factor support every 2 weeks for 4 cycles, followed by docetaxel + lapatinib for four 21-day cycles, followed by surgery. Dexamethasone was administered twice-a-day for 3 days, starting 24 hours before the docetaxel inf...	[ 0 ]	8	[ 0, 0, 0, 0, 0, 0, 0, 0 ]	intervention 1: 1250 mg, tablets, oral daily during treatment with docetaxel (3-week cycles x 4 cycles) intervention 2: 60 mg/m2, intravenously every 2 weeks for 4 cycles. Given as first treatment with cyclophosphamide. intervention 3: 600 mg/m2, intravenously every 2 weeks for 4 cycles. Given as first treatment with d...	intervention 1: Lapatinib intervention 2: Doxorubicin intervention 3: Cyclophosphamide intervention 4: Docetaxel intervention 5: Pegfilgrastim intervention 6: Filgrastim intervention 7: Dexamethasone intervention 8: Trastuzumab	2	San Jose \| California \| United States \| -121.89496 \| 37.33939 Stanford \| California \| United States \| -122.16608 \| 37.42411	21	0	0	0	NCT00404066	1COMPLETED	2011-03-01	2006-10-01	George Albert Fisher	7OTHER	false	false	false	null	0	0	0	0	0
[ 3, 4 ]	61	RANDOMIZED	PARALLEL	0TREATMENT	2DOUBLE	false	1FEMALE	null	This research study is designed to look at the effectiveness of bupropion for reducing binge eating in overweight persons with binge eating problems. Participants in the study will receive either bupropion or placebo ("sugar" pill, inactive medication) as an outpatient for eight weeks. In addition, participants will be...	The proposed study is an 8-week randomized placebo-controlled trial to test the efficacy of bupropion in treating overweight women with binge eating disorder (BED). Bupropion is an antidepressant that has demonstrated efficacy in smoking cessation and some efficacy in obesity treatment. Since cravings and depressed moo...	Binge Eating Disorder Obesity	Binge eating Obesity Medication Craving Emotional eating	null	2	arm 1: Bupropion arm 2: Placebo	[ 0, 2 ]	2	[ 0, 10 ]	intervention 1: 300 mg per day for 8 weeks intervention 2: Placebo	intervention 1: bupropion intervention 2: Placebo	1	New Haven \| Connecticut \| United States \| -72.92816 \| 41.30815	61	0	0	0	NCT00414167	1COMPLETED	2011-03-01	2005-12-01	Yale University	7OTHER	false	false	false	null	0	0	0	0	0
[ 2, 3 ]	20	RANDOMIZED	PARALLEL	0TREATMENT	4QUADRUPLE	false	0ALL	null	The purpose of this study is to assess the safety and tolerability of Rituximab in refractory scleritis and non-infectious orbital inflammation.	null	Scleritis Orbital Disease		null	2	arm 1: Subjects with Scleritis arm 2: Subjects with Orbital Inflammation	[ 0, 0 ]	1	[ 0 ]	intervention 1: Two 500 or 1000mg infusions over 2 weeks with the option of retreating after 6 months if initial improvement was seen.	intervention 1: Rituximab	1	Portland \| Oregon \| United States \| -122.67621 \| 45.52345	22	0	0	0	NCT00415506	1COMPLETED	2011-03-01	2007-01-01	Oregon Health and Science University	7OTHER	false	false	false	null	0	0	0	0	0
[ 3 ]	11	NA	SINGLE_GROUP	0TREATMENT	0NONE	false	0ALL	false	With upright postures, there is an immediate redistribution of blood to the dependent circulation; venous return and central venous filling pressure are reduced, resulting in diminution of cardiac output and blood pressure. These hemodynamic alterations stimulate the baroreceptor reflex, which is mediated via the centr...	In individuals with SCI, blood pressure regulation is altered compared to the non-SCI population and relates to the degree of sympathetic vascular denervation. The inadequate release of norepinephrine with postural change is a primary component of OH and several reports have documented significantly reduced plasma nore...	Orthostatic Hypotension Spinal Cord Injury	Blood pressure Orthostatic hypotension Spinal Cord Injury Sympathetic vascular control Midodrine	null	1	arm 1: Blood pressure response during HUT following administration of Midodrine Hydrochloride compared with no drug.	[ 0 ]	1	[ 0 ]	intervention 1: Alpha1-agonist, exerts its actions via activation of the alpha-adrenergic receptors of the arteriolar and venous vasculature, producing an increase in vascular tone and elevation of blood pressure.	intervention 1: Midodrine Hydrochloride	1	The Bronx \| New York \| United States \| -73.86641 \| 40.84985	11	0	0	0	NCT00426842	1COMPLETED	2011-03-01	2007-01-01	James J. Peters Veterans Affairs Medical Center	1FED	false	false	false	null	0	0	0	0	0
[ 3 ]	19	RANDOMIZED	CROSSOVER	0TREATMENT	4QUADRUPLE	false	0ALL	false	Pilot data indicates that pentazocine decreases manic symptoms in hospitalized individuals. To follow up these initial findings, we plan to conduct a larger, more rigorous, double-blind study. We will examine whether pentazocine, an agent with kappa-opiate activity, decreases manic symptoms.	Dysregulation of the opioid system may underlie the pathophysiology of mood disorders, such as bipolar disorder. Drugs that modulate the opioid system might be effective treatments for bipolar disorder. The profile and actions of the kappa-opioid system make drugs that target this system particularly promising as a tre...	Bipolar Disorder Schizoaffective Disorder Manic Disorder Mania Manic State	bipolar disorder bipolar mania schizoaffective disorder schizoaffective mania mania kappa opiates opiates	null	2	arm 1: In the first leg of the study, pentazocine will be given to subjects randomly assigned to this group. On Day 1, subjects will receive 50mg of pentazocine followed by a second dose of 50mg two hours later. On Day 2, subjects in this group will be given 0.25mg of Lorazepam followed by a second dose of 0.25mg two h...	[ 1, 1 ]	2	[ 0, 0 ]	intervention 1: see arms description intervention 2: see arms description	intervention 1: Pentazocine intervention 2: Lorazepam	1	Belmont \| Massachusetts \| United States \| -71.17867 \| 42.39593	38	0	0	0	NCT00431184	1COMPLETED	2011-03-01	2007-01-01	Mclean Hospital	7OTHER	false	false	false	null	0	0	0	0	0
[ 3 ]	21	RANDOMIZED	PARALLEL	0TREATMENT	3TRIPLE	true	1FEMALE	null	Medications used to increase breast milk production increase prolactin secretion, the main hormone of lactation. There are no FDA approved medications used to improve breast feeding, but metoclopramide is used off-label and can have intolerable side effects. We examined the biological activity and safety of recombinant...	There are no FDA approved medications in the U.S. to augment lactation. Metoclopramide is used off-label but can have intolerable side effects. We examined the biological activity and safety of recombinant human prolactin (r-hPRL) as preliminary data for its use to augment lactation. Healthy, non-postpartum women (n=21...	Healthy	galactorrhea prolactin bone turnover menstrual cycle Control Groups Women	null	2	arm 1: Recombinant Human Prolactin 60 mcg/kg once daily subcutaneous injection arm 2: Normal saline placebo subcutaneous injection	[ 0, 2 ]	1	[ 0 ]	intervention 1: None	intervention 1: Recombinant Human Prolactin	1	Boston \| Massachusetts \| United States \| -71.05977 \| 42.35843	21	0	0	0	NCT00438490	1COMPLETED	2011-03-01	2002-04-01	Massachusetts General Hospital	7OTHER	false	false	false	null	0	0	0	0	0
[ 5 ]	8	NA	SINGLE_GROUP	0TREATMENT	0NONE	false	0ALL	false	The purpose of this 8-week study is to compare the effects of switching from intravenous Flolan to intravenous Remodulin therapy. Remodulin (treprostinil sodium) is an approved therapy for pulmonary arterial hypertension (PAH). Unlike Flolan, Remodulin does not need to be mixed daily and is stable at room temperature, ...	Pulmonary arterial hypertension (PAH), which is defined as an elevation in pulmonary arterial pressure and pulmonary vascular resistance, is a severe hemodynamic abnormality common to a variety of diseases and syndromes. Elevation in pulmonary arterial pressure causes an increase in right ventricular afterload, impairi...	Pulmonary Arterial Hypertension	pulmonary hypertension PAH Remodulin treprostinil Quality of Life rapid switch	null	1	arm 1: IV treprostinil continuous infusion via Crono Five infusion pump.	[ 0 ]	2	[ 0, 1 ]	intervention 1: rapid switch from intravenous epoprostenol on the CADD ambulatory pump to intravenous Remodulin on the Crono Five ambulatory pump intervention 2: Used for administration of IV Remodulin (treprostinil)	intervention 1: treprostinil intervention 2: Crono Five ambulatory pump	3	San Francisco \| California \| United States \| -122.41942 \| 37.77493 New York \| New York \| United States \| -74.00597 \| 40.71427 Oklahoma City \| Oklahoma \| United States \| -97.51643 \| 35.46756	8	0	0	0	NCT00439946	6TERMINATED	2011-03-01	2007-02-01	United Therapeutics	4INDUSTRY	false	false	false	null	0	0	0	0	0
[ 3, 4 ]	1,219	RANDOMIZED	PARALLEL	1PREVENTION	3TRIPLE	true	0ALL	true	This study tested whether taking a pill of tenofovir and emtricitabine (two antiretroviral medicines) was safe for sexually-active young adults in Botswana without HIV infection and whether it reduced their risk of getting an HIV infection.	Twelve hundred and nineteen healthy, sexually active women and men, 18-39 years old, without HIV infection were enrolled in Francistown and Gaborone, Botswana. They were provided with free male and female condoms, repeated individualized risk-reduction counseling, diagnosis and treatment of sexually transmitted disease...	HIV Infections	HIV incidence HIV prevention Tenofovir Emtricitabine Botswana HIV seronegativity	null	2	arm 1: Eligible participants were randomized to oral Tenofovir Disoproxil Fumarate 300 mg + Emtricitabine 200 mg (TDF-FTC) once daily in the form of a single tablet. The ratio of randomization was 1:1. Participants randomized to the active arm received male and female condoms, risk reduction counseling, adherence couns...	[ 1, 2 ]	2	[ 0, 0 ]	intervention 1: None intervention 2: None	intervention 1: Tenofovir Disoproxil Fumarate 300 mg + Emtricitabine 200 mg intervention 2: Placebo Oral Tablet	2	Atlanta \| Georgia \| United States \| -84.38798 \| 33.749 Gaborone \| N/A \| Botswana \| 25.90859 \| -24.65451	1,219	0	0	0	NCT00448669	1COMPLETED	2011-03-01	2007-03-01	Centers for Disease Control and Prevention	1FED	false	false	false	null	0	0	0	0	-0
[ 0 ]	39	NA	SINGLE_GROUP	2DIAGNOSTIC	0NONE	false	0ALL	true	RATIONALE: Diagnostic procedures, such as thoracoscopic sentinel lymph node biopsy, may help find breast cancer that has spread to lymph nodes between the breasts. It may also help doctors plan the best treatment. PURPOSE: This clinical trial is studying how well thoracoscopic sentinel lymph node biopsy finds sentinel...	OBJECTIVES: * Determine the occurrence rate of internal mammary sentinel lymph nodes in patients with medially or centrally located stage I or II breast cancer. * Determine the safety, feasibility, and success rate of thorascopic internal mammary sentinel lymph node biopsy in these patients. * Determine the rate of me...	Breast Cancer	stage I breast cancer stage II breast cancer male breast cancer	null	1	arm 1: None	[ 0 ]	6	[ 0, 3, 3, 3, 3, 4 ]	intervention 1: Administered pre-surgery; injection of 2 cc of Isosulfan Blue in four equal aliquots of 0.5 cc as routinely done for the axillary sentinel node procedure. intervention 2: Axillary Lymph Node Dissection intervention 3: The surgery will be performed under general anesthesia with a single lumen endo-trache...	intervention 1: Isosulfan blue intervention 2: Axillary Lymph Node Dissection intervention 3: Surgery intervention 4: Sentinel Lymph Node Biopsy intervention 5: Thoracoscopic Surgery intervention 6: Technetium Tc 99m Sulfur Colloid	1	Miami \| Florida \| United States \| -80.19366 \| 25.77427	34	0	0	0	NCT00450723	1COMPLETED	2011-03-01	2004-05-01	University of Miami	7OTHER	false	false	false	null	0	0	0	0	0
[ 3 ]	24	NA	SINGLE_GROUP	0TREATMENT	0NONE	false	0ALL	true	This phase II trial is studying how well giving MS-275 together with GM-CSF works in treating patients with myelodysplastic syndrome and/or relapsed or refractory acute myeloid leukemia. MS-275 may stop the growth of cancer cells by blocking some of the enzymes needed for cell growth and by blocking blood flow to the c...	PRIMARY OBJECTIVE: I. Determine clinical response in patients with myelodysplastic syndromes and/or relapsed or refractory acute myeloid leukemia or acute lymphocytic leukemia treated with MS-275 in combination with sargramostim (GM-CSF). SECONDARY OBJECTIVES: I. Determine the clinical activity of this regimen, in t...	Adult Acute Lymphoblastic Leukemia in Remission Adult Acute Megakaryoblastic Leukemia (M7) Adult Acute Minimally Differentiated Myeloid Leukemia (M0) Adult Acute Monoblastic Leukemia (M5a) Adult Acute Monocytic Leukemia (M5b) Adult Acute Myeloblastic Leukemia With Maturation (M2) Adult Acute Myeloblastic Leukemia Witho...		null	1	arm 1: Patients receive oral MS-275 on days 1, 8, 15, and 22. Patients also receive sargramostim (GM-CSF) subcutaneously once daily on days 1-42 in courses 3 and 5 and on days 1-35 in courses 1, 2, 4, and 6. Treatment repeats every 6 weeks for 2-6 courses in the absence of disease progression or unacceptable toxicity. ...	[ 0 ]	2	[ 0, 0 ]	intervention 1: Given PO intervention 2: Given SC	intervention 1: entinostat intervention 2: sargramostim	1	Baltimore \| Maryland \| United States \| -76.61219 \| 39.29038	24	0	0	0	NCT00462605	1COMPLETED	2011-03-01	2007-04-01	National Cancer Institute (NCI)	0NIH	false	false	false	null	0	0	0	0	0
[ 3 ]	21	NA	SINGLE_GROUP	0TREATMENT	0NONE	false	0ALL	null	RATIONALE: Gefitinib may stop the growth of kidney cancer by blocking blood flow to the tumor and by blocking some of the enzymes needed for cell growth. PEG-interferon alfa-2b may interfere with the growth of tumor cells and slow the growth of kidney cancer. Giving gefitinib together with PEG-interferon alfa-2b may ki...	OBJECTIVES: Primary * Determine the 6-month progression-free survival of patients with unresectable or metastatic renal cell carcinoma treated with gefitinib and PEG-interferon alfa-2b. Secondary * Determine the response rate (by RECIST criteria), duration of response, time to treatment failure, and overall surviva...	Kidney Cancer	recurrent renal cell cancer stage IV renal cell cancer stage III renal cell cancer	null	1	arm 1: Gefitinib administered at a dose of 250 mg orally once daily for 12 weeks. PEG-IFNa at 4.0 µg/kg/wk administered subcutaneously once weekly for 6 weeks (cycle repeated once for a total of 2 cycles).	[ 0 ]	2	[ 2, 0 ]	intervention 1: PEG-Interferon will be administered subcutaneously (sq) once weekly for 6 weeks intervention 2: ZD1839 will be administered at a dose of 250 mg orally once daily,	intervention 1: PEG-interferon alfa-2b intervention 2: gefitinib	3	Duarte \| California \| United States \| -117.97729 \| 34.13945 Los Angeles \| California \| United States \| -118.24368 \| 34.05223 Sacramento \| California \| United States \| -121.4944 \| 38.58157	21	0	0	0	NCT00467077	6TERMINATED	2011-03-01	2004-09-01	California Cancer Consortium	5NETWORK	false	false	false	null	0	0	0	0	0
[ 4 ]	7,141	RANDOMIZED	PARALLEL	0TREATMENT	4QUADRUPLE	false	0ALL	false	The purpose of this study is to find out if nesiritide (a human B-type natriuretic peptide/hBNP) as compared to placebo, plus the usual treatment for acute decompensated heart failure, helps to improve breathing difficulties, reduce heart failure readmissions to hospitals, and helps patients live longer.	Acute Decompensated Heart Failure (ADHF) is the inability of the heart to pump efficiently, which can result in symptoms like shortness of breath at rest or with minimal activity. ADHF is a condition in which the heart cannot perform the necessary circulation of blood through the body. This is a randomized (study medic...	Heart Decompensation	Heart Decompensation Dyspnea Heart failure Nesiritide Decompensated ADHF	null	2	arm 1: Nesiritide 0.01 mcg/kg/min intravenous (IV) infusion (with or without 2 mcg/kg bolus) for 24 to 168 hours (hrs) arm 2: Placebo matching placebo infusion:0.01 mcg/kg/min IV infusion (with or without 2 mcg/kg bolus) for 24 to 168 hrs	[ 0, 2 ]	2	[ 0, 0 ]	intervention 1: 0.01 mcg/kg/min IV infusion (with or without 2 mcg/kg bolus) for 24 to 168 hrs intervention 2: matching placebo infusion:0.01 mcg/kg/min IV infusion (with or without 2 mcg/kg bolus) for 24 to 168 hrs	intervention 1: Nesiritide intervention 2: Placebo	328	Huntsville \| Alabama \| United States \| -86.58594 \| 34.7304 Mobile \| Alabama \| United States \| -88.04305 \| 30.69436 Anchorage \| Alaska \| United States \| -149.90028 \| 61.21806 Gilbert \| Arizona \| United States \| -111.78903 \| 33.35283 Scottsdale \| Arizona \| United States \| -111.89903 \| 33.50921 Fort Smith \| Arkansas \| Uni...	7,007	0	0	0	NCT00475852	1COMPLETED	2011-03-01	2007-05-01	Scios, Inc.	4INDUSTRY	false	false	false	null	0	0	0	0	0
[ 3 ]	18	NA	SINGLE_GROUP	5SCREENING	0NONE	true	0ALL	false	The purpose of the study is to see whether treating alopecia areata with injections of the corticosteroid, Triamcinolone acetonide 10mg/cc (Kenalog-10), has an impact on the adrenal glands.	1. To determine the effects of intralesional Triamcinolone Acetonide 10mg/cc (Kenalog 10) use for the treatment of alopecia areata on adrenal function. 2. To evaluate the efficacy of intralesional corticosteroids (Kenalog-10)on hair regrowth in moderate to severe alopecia areata. 18 subjects with moderate to severe al...	Alopecia Areata		null	1	arm 1: Patients receiving Triamcinolone Acetonide 10 ml (Kenalog-10) intralesional injections.	[ 0 ]	1	[ 0 ]	intervention 1: Triamcinolone Acetonide 10 mg/ml (Kenalog-10) intralesional injection	intervention 1: Triamcinolone Acetonide 10 mg/mL (Kenalog-10)	1	Minneapolis \| Minnesota \| United States \| -93.26384 \| 44.97997	18	0	0	0	NCT00484679	1COMPLETED	2011-03-01	2007-05-01	University of Minnesota	7OTHER	false	false	false	null	0	0	0	0	0
[ 3 ]	6	NA	SINGLE_GROUP	0TREATMENT	0NONE	false	0ALL	false	Primary Objective: * Overall Response Rate (ORR). Secondary Objectives: * The Duration of Response (DR) and Time to Treatment Progression (TTP) in all patients and in the responders. * Complete Responses (CR)/Complete Responses unconfirmed (CRu), and Partial Responses (PR). * Time to next anticancer therapy (TTNT).	\^90 Y Ibritumomab tiuxetan and rituximab are both designed to attach to lymphoma cells, causing them to die. Before you can start treatment on this study, you will have what are called "screening tests." These tests will help the doctor decide if you are eligible to take part in this study. You will have a physical e...	Lymphoma	Indolent Lymphoma Extranodal Marginal Nodal Marginal Zone Splenic Marginal MALT Type Zevalin Ibritumomab Tiuxetan Rituximab	null	1	arm 1: Rituximab 250 mg/m² intravenous (IV) Days 1 and 8, 111In Ibritumomab Tiuxetan (5mCi of 111In, 1.6 mg of Ibritumomab Tiuxetan) IV (over 10 minutes) on Day 1; and 90Y Ibritumomab Tiuxetan 0.3 or 0.4 mCi/kg IV (over 10 minutes) on Day 8 after the Day 8 of Rituximab.	[ 0 ]	3	[ 0, 0, 0 ]	intervention 1: .3 mCi IV Over 10 Minutes x 1 Day intervention 2: 250 mg/m\^2 IV Over 6 to 8 Hours intervention 3: 1.6 mg IV Over 10 Minutes x 1 Day	intervention 1: Zevalin intervention 2: Rituximab intervention 3: ^111 In Ibritumomab Tiuxetan	1	Houston \| Texas \| United States \| -95.36327 \| 29.76328	5	0	0	0	NCT00493454	6TERMINATED	2011-03-01	2006-04-01	M.D. Anderson Cancer Center	7OTHER	false	false	false	null	0	0	0	0	0
[ 4 ]	300	RANDOMIZED	PARALLEL	0TREATMENT	4QUADRUPLE	false	0ALL	false	VIVITROL is indicated for the treatment of alcohol dependence in patients who are able to abstain from alcohol in an outpatient setting prior to initiation of treatment with VIVITROL. This Phase 3B trial was designed to evaluate the efficacy and safety of VIVITROL versus placebo. Injections were administered to patient...	The study consisted of 2 parts, Part A and Part B. Part A was a double-blind, placebo-controlled assessment of safety and efficacy of VIVITROL versus placebo for 3 months. Part B was an open-label extension to assess longer-term safety, durability of effect, and health economics of VIVITROL when administered for up to ...	Alcohol Dependence	Addiction Alcoholism Inpatient detoxification	null	2	arm 1: Administered via intramuscular (IM) injection once every 4 weeks. arm 2: Administered via IM injection once every 4 weeks.	[ 1, 2 ]	2	[ 0, 0 ]	intervention 1: Administered via IM injection once every 4 weeks. intervention 2: Administered via IM injection once every 4 weeks.	intervention 1: VIVITROL 380 mg intervention 2: Placebo for VIVITROL 380 mg	0	null	300	0	0	0	NCT00501631	1COMPLETED	2011-03-01	2007-07-01	Alkermes, Inc.	4INDUSTRY	false	false	false	null	0	0	0	0	0
[ 3 ]	30	NA	SINGLE_GROUP	0TREATMENT	0NONE	false	0ALL	true	The investigators hypothesize that the combination of Gemzar®, Abraxane® and Avastin will increase the progression-free survival (PFS) in patients with first line metastatic breast cancer and in patients who received neoadjuvant and/or adjuvant chemotherapy present with definable metastatic disease, 6 or more months af...	This is a phase 2, single arm study. Participants will be treated with combination Gemzar, Abraxane and Avastin therapy until disease progression. Each treatment cycle is 28 days.	Breast Cancer	stage IV breast cancer recurrent breast cancer	null	1	arm 1: Each treatment cycle is 28 days. Participants will be treated until disease progression: * Gemcitabine: 1500 mg/m2 body surface area (BSA) intravenously (IV) over 30 minutes (+/- 5 minutes) on days 1 and 15 of each cycle, followed by; * Abraxane: 150 mg/m2 IV over 30 minutes (+/- 5 minutes) on days 1 and 15 of ...	[ 0 ]	3	[ 0, 0, 0 ]	intervention 1: None intervention 2: None intervention 3: None	intervention 1: Avastin intervention 2: Gemcitabine intervention 3: Abraxane	1	Miami \| Florida \| United States \| -80.19366 \| 25.77427	29	0	0	0	NCT00503906	1COMPLETED	2011-03-01	2007-06-01	University of Miami	7OTHER	false	false	false	null	0	0	0	0	0
[ 3 ]	43	RANDOMIZED	PARALLEL	0TREATMENT	4QUADRUPLE	false	0ALL	false	This study will evaluate the effectiveness of galantamine and CDP-choline in improving symptoms associated with schizophrenia.	Schizophrenia is a life-long brain disorder affecting approximately 1 percent of Americans each year. Schizophrenia can be extremely disabling, causing people to hear voices, experience paranoia or hallucinations, believe that others are controlling their thoughts, and even fail at maintaining a job or caring for thems...	Schizophrenia	Schizoaffective Disorder Acetylcholine Nicotinic Receptors Nicotine Galantamine negative symptoms	null	2	arm 1: Participants assigned to receive galantamine and CDP-choline arm 2: Participants assigned to receive placebo	[ 0, 2 ]	4	[ 0, 0, 0, 0 ]	intervention 1: Galantamine will be titrated to 24 mg/day over 2 weeks. Participants will receive 8 mg/day in two divided doses for 1 week, 16 mg/day in two divided doses for 1 week, and 24 mg/day in two divided doses beginning in Week 3. They will be maintained on 24 mg/day for the remainder of the study. intervention...	intervention 1: Galantamine intervention 2: CDP-choline intervention 3: Placebo intervention 4: risperidone, olanzapine, quetiapine, ziprasidone, and/or aripiprazole	1	Washington D.C. \| District of Columbia \| United States \| -77.03637 \| 38.89511	43	0	0	0	NCT00509067	1COMPLETED	2011-03-01	2007-11-01	Georgetown University	7OTHER	false	false	false	null	0	0	0	0	0
[ 3, 4 ]	20	RANDOMIZED	PARALLEL	0TREATMENT	0NONE	false	0ALL	true	The primary objective of the study was to determine the effects of 10-week adjunctive supplementation with 2 doses of LCn-3 fatty acids (fish oil) on cortical functional activity and biochemistry in adolescents with MDD. The primary prediction was that LCn-3 fatty acid supplementation would dose-dependently increase p...	This study is a 10-week open-label EPA+DHA treatment trial in adolescent (aged 12-18 years) patients with major depressive disorder exhibiting partial response to SSRI medications. After a screening visit, patients were randomized (stratified by gender) to open-label fish oil supplements at a fixed dose of either 2.4 g...	Major Depressive Disorder	Sadness Insomnia Loss of appetite Fatigue Trouble thinking	null	2	arm 1: Capsule omega-3 fatty acids 2.4g/day (4 capsules/day) arm 2: Liquid omega-3 fatty acid 15 g/day (2 tablespoons/day)	[ 0, 0 ]	2	[ 0, 0 ]	intervention 1: Omega-3 Fatty Acids 2.4g/day in capsule form (4 capsules per day) intervention 2: Liquid omega-3 fatty acid 15 g/day (2 tablespoons/day)	intervention 1: Low Dose Fish Oil intervention 2: High Dose Fish Oil	1	Cincinnati \| Ohio \| United States \| -84.51439 \| 39.12711	20	0	0	0	NCT00511810	1COMPLETED	2011-03-01	2007-08-01	University of Cincinnati	7OTHER	false	false	false	null	0	0	0	0	0
[ 3 ]	9	NA	SINGLE_GROUP	0TREATMENT	0NONE	false	0ALL	true	This phase II trial is studying the how well saracatinib works in treating patients with metastatic or recurrent head and neck cancer. Saracatinib may stop the growth of tumor cells by blocking some of the enzymes needed for cell growth	PRIMARY OBJECTIVES: I. To determine the median progression-free survival for patients with advanced or recurrent squamous cell carcinoma of the head and neck (HNSCC) treated with AZD0530 (saracatinib). SECONDARY OBJEC TIVES: I. To determine overall survival for patients with advanced or recurrent HNSCC treated with ...	Metastatic Squamous Neck Cancer With Occult Primary Squamous Cell Carcinoma Recurrent Metastatic Squamous Neck Cancer With Occult Primary Recurrent Squamous Cell Carcinoma of the Hypopharynx Recurrent Squamous Cell Carcinoma of the Larynx Recurrent Squamous Cell Carcinoma of the Lip and Oral Cavity Recurrent Squamous C...		null	1	arm 1: Patients receive saracatinib PO or by PEG tube QD on days 1-56. Courses repeat every 8 weeks in the absence of disease progression or unacceptable toxicity.	[ 0 ]	2	[ 0, 10 ]	intervention 1: Given PO intervention 2: Correlative studies	intervention 1: saracatinib intervention 2: laboratory biomarker analysis	1	New York \| New York \| United States \| -74.00597 \| 40.71427	9	0	0	0	NCT00513435	1COMPLETED	2011-03-01	2007-07-01	National Cancer Institute (NCI)	0NIH	false	false	false	null	0	0	0	0	0
[ 3 ]	9	NA	SINGLE_GROUP	0TREATMENT	0NONE	false	0ALL	true	RATIONALE: Sunitinib may stop the growth of tumor cells by blocking some of the enzymes needed for cell growth and by blocking blood flow to the tumor. Giving sunitinib before surgery may make the tumor smaller and reduce the amount of normal tissue that needs to be removed. PURPOSE: This phase II trial is studying th...	OBJECTIVES: Primary * To determine the pathologic complete response rate of sunitinib malate in patients with muscle-invasive locally advanced transitional cell carcinoma (TCC) of the bladder. * To evaluate the safety and tolerability of sunitinib malate administered prior to radical cystectomy, including surgical ou...	Bladder Cancer	transitional cell carcinoma of the bladder stage II bladder cancer stage III bladder cancer stage IV bladder cancer	null	1	arm 1: Drug	[ 0 ]	1	[ 0 ]	intervention 1: 50mg PO daily 4 weeks on -2 weeks off	intervention 1: sunitinib malate	1	Cleveland \| Ohio \| United States \| -81.69541 \| 41.4995	9	0	0	0	NCT00526656	1COMPLETED	2011-03-01	2007-09-01	Case Comprehensive Cancer Center	7OTHER	false	false	false	null	0	0	0	0	0
[ 5 ]	28	RANDOMIZED	CROSSOVER	0TREATMENT	0NONE	false	0ALL	false	To compare the effect of high-dose valacyclovir (1 gram orally twice daily) versus standard-dose acyclovir (400 mg orally twice daily) on the frequency of genital HSV reactivation and on plasma HIV-1 levels among HSV-2/HIV-1 co-infected individuals. The investigators hypothesize that high-dose valacyclovir will result ...	We propose to conduct a randomized, open-label, cross-over study of 38 individuals who are HIV-1 seropositive and HSV-2 seropositive. Both men and women will be recruited for the study. Participants must not be on antiretroviral therapy and must not be planning to initiate antiretroviral therapy during the anticipated ...	Genital Herpes HIV Infection	Herpes Simplex Virus Type 2 Human Immunodeficiency Virus Treatment Naive	null	2	arm 1: acyclovir 400 mg orally twice daily for 12 weeks. arm 2: valacyclovir 1000 mg orally twice daily for 12 weeks.	[ 1, 0 ]	2	[ 0, 0 ]	intervention 1: valacyclovir 1000 mg orally twice daily for 12 weeks. intervention 2: acyclovir 400 mg orally twice daily for 12 weeks.	intervention 1: valacyclovir intervention 2: acyclovir	1	Seattle \| Washington \| United States \| -122.33207 \| 47.60621	62	0	0	0	NCT00527618	1COMPLETED	2011-03-01	2007-12-01	University of Washington	7OTHER	false	false	false	null	0	0	0	0	0
[ 4 ]	619	RANDOMIZED	PARALLEL	0TREATMENT	2DOUBLE	false	0ALL	null	This 2-arm study assessed the safety and efficacy of tocilizumab versus placebo, both in combination with disease modifying antirheumatic drugs (DMARDs), in regard to reduction in signs and symptoms, in patients with moderate to severe active rheumatoid arthritis with an inadequate response to DMARDs. Patients were ran...	null	Rheumatoid Arthritis		null	2	arm 1: None arm 2: None	[ 0, 2 ]	3	[ 0, 0, 0 ]	intervention 1: Tocilizumab intravenously at a dose of 8 mg/kg over a 1-hour infusion, every 4 weeks, for a total of 6 infusions. intervention 2: Placebo IV over a 1-hour infusion, every 4 weeks, for a total of 6 infusions. intervention 3: As prescribed. The following DMARDs were permitted in this study: methotrexate (...	intervention 1: Tocilizumab intervention 2: Placebo intervention 3: Permitted DMARDs	157	Birmingham \| Alabama \| United States \| -86.80249 \| 33.52066 Birmingham \| Alabama \| United States \| -86.80249 \| 33.52066 Birmingham \| Alabama \| United States \| -86.80249 \| 33.52066 Montgomery \| Alabama \| United States \| -86.29997 \| 32.36681 Lake Havasu City \| Arizona \| United States \| -114.32245 \| 34.4839 Paradise Valle...	787	0	0	0	NCT00531817	1COMPLETED	2011-03-01	2007-10-01	Hoffmann-La Roche	4INDUSTRY	false	false	false	null	0	0	0	0	0
[ 3 ]	294	RANDOMIZED	SINGLE_GROUP	0TREATMENT	4QUADRUPLE	false	0ALL	false	ARI109924 will be a 2-year, multicentre, randomised, double-blind, placebo-controlled trial assessing the efficacy and safety of dutasteride in extending time to prostate specific antigen (PSA) doubling in men who have been treated for clinically localised prostate cancer (PCa) with a radical therapy (radical prostatec...	A Randomised, Double-Blind, Placebo-Controlled Trial Assessing the Efficacy and Safety of Dutasteride (AVODART™) 0.5 mg in Extending the Time to PSA Doubling in Men with Prostate Cancer and Biochemical Failure (PSA increase) after Radical Therapy with Curative Intent (ARTS - AVODART after Radical Therapy for prostate c...	Neoplasms, Prostate Prostate Cancer After a Radical Treatment	Prostate Cancer AVODART PSA dutasteride PSADT Prostate specific antigen radical therapy doubling time	null	2	arm 1: Patients will receive a 3-month supply of study drug or placebo. Patients will be instructed to take one capsule by mouth once daily. Study medication will be supplied at 3-month intervals during scheduled clinic visits for a total of 24 months. arm 2: Patients will receive a 3-month supply of study drug or plac...	[ 0, 2 ]	2	[ 0, 10 ]	intervention 1: 0.5 mg administered orally once daily intervention 2: Patients will be randomized at Visit 2 in 1:1 ratio to receive either 0.5 mg dutasteride or placebo	intervention 1: Avodart intervention 2: placebo	66	Tallinn \| N/A \| Estonia \| 24.75353 \| 59.43696 Tallinn \| N/A \| Estonia \| 24.75353 \| 59.43696 Kouvola \| N/A \| Finland \| 26.7 \| 60.86667 Oulu \| N/A \| Finland \| 25.46816 \| 65.01236 Tampere \| N/A \| Finland \| 23.78712 \| 61.49911 Angers \| N/A \| France \| -0.55202 \| 47.47156 Chambéry \| N/A \| France \| 5.92079 \| 45.56628 Créteil ...	294	0	0	0	NCT00558363	1COMPLETED	2011-03-01	2007-11-01	GlaxoSmithKline	4INDUSTRY	false	false	false	null	0	0	0	0	0
[ 4 ]	207	RANDOMIZED	PARALLEL	0TREATMENT	2DOUBLE	false	0ALL	false	The purpose of this study is to compare the safety and efficacy of zonisamide with placebo.	This will be a double-blind, randomised, study comparing zonisamide with placebo: each arm will consist of 102 subjects. Zonisamide/placebo dosing will commence with a dose of 1 mg/kg. Further dose increases will occur at weekly intervals until a dose of 8 mg/kg is reached at the end of Week 8. In the event of dose lim...	Epilepsy; Paediatric Partial Onset Seizures	Epilepsy paediatric partial onset seizures	null	2	arm 1: Participants had a starting dose of 1 mg/kg/day of placebo matching Zonisamide. Dose was titrated upwards with weekly dose increases until a dose of 8 mg/kg/day was reached at the end of the Titration Period (Week 8). Dose during the Maintenance Period remained unchanged from Week 8. arm 2: Participants had a st...	[ 2, 0 ]	2	[ 0, 0 ]	intervention 1: 8mg/kg per day for approximately 24 weeks. intervention 2: None	intervention 1: Zonisamide intervention 2: Placebo	43	Brussels \| N/A \| Belgium \| 4.34878 \| 50.85045 Brussels \| N/A \| Belgium \| 4.34878 \| 50.85045 Ghent \| N/A \| Belgium \| 3.71667 \| 51.05 Leuven \| N/A \| Belgium \| 4.70093 \| 50.87959 Tallinn \| N/A \| Estonia \| 24.75353 \| 59.43696 Tartu \| N/A \| Estonia \| 26.72509 \| 58.38062 Bordeaux \| N/A \| France \| -0.5805 \| 44.84044 Garches \|...	207	0	0	0	NCT00566254	1COMPLETED	2011-03-01	2008-12-01	Eisai Inc.	4INDUSTRY	false	false	false	null	0	0	0	0	0
[ 4 ]	20	RANDOMIZED	PARALLEL	0TREATMENT	0NONE	false	0ALL	false	Add three drugs, bortezomib, thalidomide, and dexamethasone (VTD) to the high dose chemotherapy regimen immediately before transplant (DPACE/Melphalan) to try to improve myeloma response and acquire longer survival for participants.	null	Multiple Myeloma		null	2	arm 1: DPACE Induction, Melphalan/DPACE Transplant 1, BEAM Transplant 2, DPACE Consolidation, Dexamethasone Maintenance with Interim dexamethasone between treatment phases arm 2: DPACE Induction, Melphalan/DPACE + VTD Transplant 1, BEAM + VTD Transplant 2, DPACE Consolidation, Dexamethasone Maintenance with Interim dex...	[ 0, 0 ]	22	[ 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 3, 0, 0, 0, 0, 0, 0, 0 ]	intervention 1: 20 mg Days 1-4 every 3 weeks in the interim between treatment phases and during maintenance intervention 2: 40 mg Days 1-4 intervention 3: 10 mg/m2 by continuous infusion Days 1-4 intervention 4: 10 mg/m2 by continuous infusion Days 1-4 intervention 5: 400 mg/m2 by continuous infusion Days 1-4 intervent...	intervention 1: Interim/Maintenance Dexamethasone intervention 2: Induction/Consolidation Dexamethasone intervention 3: Induction/Consolidation Cisplatin intervention 4: Induction/Consolidation Adriamycin intervention 5: InductionConsolidation Cyclophosphamide intervention 6: Induction/Consolidation Etoposide intervent...	1	Little Rock \| Arkansas \| United States \| -92.28959 \| 34.74648	20	0	0	0	NCT00574080	6TERMINATED	2011-03-01	2006-07-01	University of Arkansas	7OTHER	false	false	false	null	0	0	0	0	0
[ 0 ]	24	RANDOMIZED	PARALLEL	0TREATMENT	0NONE	false	0ALL	false	Type I diabetes (T1DM) is the second most common chronic illness effecting children in the USA. Worldwide, Type I diabetes is increasing in incidence, and its underlying etiology remains elusive. Nevertheless, recent data supports the notion that early and intensive management of Type I diabetes can 1) decrease long-te...	null	Diabetes Mellitus	Insulin pump Beta cell	null	2	arm 1: MDI = 3-4+ insulin injections/day, using split-mix NPH insulin + regular insulin or Lantus + Novolog® (or Humalog®). arm 2: CSII (insulin pump), using Animas Corporation insulin pump, model IR 1200.	[ 1, 0 ]	2	[ 0, 1 ]	intervention 1: MDI = 3-4+ insulin injections/day, using NPH + regular insulin or Lantus + insulin lispro; 12 month treatment duration. intervention 2: CSII (insulin pump), using Animas Corporation insulin pump, model IR 1200.	intervention 1: MDI (split-mix NPH insulin + regular insulin or Lantus + Novolog® [or Humalog®]) intervention 2: CSII (Animas Corporation insulin pump, model IR 1200)	1	Little Rock \| Arkansas \| United States \| -92.28959 \| 34.74648	24	0	0	0	NCT00574405	1COMPLETED	2011-03-01	2005-04-01	Arkansas Children's Hospital Research Institute	7OTHER	false	false	false	null	0	0	0	0	0
[ 5 ]	333	RANDOMIZED	PARALLEL	0TREATMENT	2DOUBLE	false	0ALL	false	During the run-in period, CZP will be administered at 400 mg (2 injections) at Wks 0, 2, and 4 and 200 mg with placebo (1 injection placebo, 1 injection CZP) at Wks 6, 8, 10, 12, 14 and 16. At Wk 18 patients will be grouped as responders or non-responders based on results of the ACR20 at Week 16.	Subjects with a stable methotrexate (MTX) dose enter the run-in period in which certolizumab pegol (CZP) will be administered at a dose of 400 mg (2 injections) at Weeks 0, 2, and 4 and at a dose of 200 mg with placebo (1 injection placebo, 1 injection CZP) at Weeks 6, 8, 10, 12, 14 and 16. The dose of MTX should be st...	Rheumatoid Arthritis	Rheumatoid Arthritis Joint Disease Arthritis Certolizumab pegol Cimzia	null	3	arm 1: 400 mg certolizumab pegol given every 4 weeks and placebo given every 4 weeks given as two injections (alternating injections every two weeks) arm 2: 200 mg certolizumab pegol and placebo administered every 2 weeks (one injection of each) arm 3: Placebo administered as two injections every 2 weeks	[ 1, 0, 2 ]	3	[ 0, 0, 10 ]	intervention 1: 400 mg certolizumab pegol given every 4 weeks and placebo given every 4 weeks given as two injections (alternating injections every two weeks) intervention 2: 200 mg certolizumab pegol and placebo administered every 2 weeks (one injection of each) intervention 3: placebo (saline) administered as two inj...	intervention 1: Certolizumab pegol intervention 2: Certolizumab pegol intervention 3: Placebo	66	Huntsville \| Alabama \| United States \| -86.58594 \| 34.7304 Montgomery \| Alabama \| United States \| -86.29997 \| 32.36681 Gilbert \| Arizona \| United States \| -111.78903 \| 33.35283 Paradise Valley \| Arizona \| United States \| -111.94265 \| 33.53115 Tucson \| Arizona \| United States \| -110.92648 \| 32.22174 Little Rock \| Arkans...	541	0	0	0	NCT00580840	1COMPLETED	2011-03-01	2007-12-01	UCB Pharma	4INDUSTRY	false	false	false	null	0	0	0	0	0
[ 3 ]	26	NON_RANDOMIZED	PARALLEL	0TREATMENT	0NONE	false	0ALL	false	This will be a single arm Phase II study.	LBH589 (20 mg PO) will be administered three times a week on Monday, Wednesday and Friday. Treatment will be given over 21 days followed by a 7 day rest period and repeated every 28 days. Patients will be assessed for toxicity on an ongoing basis and disease assessment will be determined every 2 treatment cycles (8 wee...	Myelodysplastic Syndromes (MDS)	Myelodysplastic Syndromes (MDS) Refractory LBH589	null	2	arm 1: Treatment with LBH589 (Panobinostat) 20 mg arm 2: Treatment with LBH589 (Panobinostat) 30 mg	[ 0, 0 ]	1	[ 0 ]	intervention 1: Panobinostat(20 mg or 30 mg PO) will be administered three times a week on Monday, Wednesday and Friday. Treatment will be given over 21 days followed by a 7 day rest period and repeated every 28 days. Patients will be assessed for toxicity on an ongoing basis and disease assessment will be determined e...	intervention 1: Panobinostat	7	Fort Myers \| Florida \| United States \| -81.84059 \| 26.62168 Gainesville \| Georgia \| United States \| -83.82407 \| 34.29788 Louisville \| Kentucky \| United States \| -85.75941 \| 38.25424 Bethesda \| Maryland \| United States \| -77.10026 \| 38.98067 Cincinnati \| Ohio \| United States \| -84.51439 \| 39.12711 Chattanooga \| Tennesse...	26	0	0	0	NCT00594230	6TERMINATED	2011-03-01	2008-01-01	SCRI Development Innovations, LLC	7OTHER	false	false	false	null	0	0	0	0	0
[ 3 ]	160	NON_RANDOMIZED	SINGLE_GROUP	0TREATMENT	0NONE	false	0ALL	null	The purpose of this study is to evaluate the safety and efficacy of E2020 in patients with Dementia with Lewy Bodies (DLB).	null	Dementia With Lewy Bodies (DLB)	Lewy Body Disease Dementia Clinical Trial Phase II E2020 donepezil hydrochloride	null	1	arm 1: None	[ 0 ]	1	[ 0 ]	intervention 1: Dosage and administration: Patients will receive oral administration of 1 tablet of 3 mg (E2020) from Day 1 to Day 14 of treatment period, 1 tablet of 5 mg (E2020) from Day 15 onwards once daily after breakfast.	intervention 1: E2020	0	null	108	0	0	0	NCT00598650	1COMPLETED	2011-03-01	2008-02-01	Eisai Co., Ltd.	4INDUSTRY	false	false	false	null	0	0	0	0	0
[ 3 ]	37	RANDOMIZED	PARALLEL	0TREATMENT	3TRIPLE	false	0ALL	false	This study will determine if acamprosate, a drug approved to treat alcoholism, decreases alcohol cravings in alcohol-dependent subjects following infusions of yohimbine and mCPP. Yohimbine causes anxiety and may provoke a desire for alcohol; mCPP induces a feeling of having had a few drinks, which often creates a desir...	Objective: The objective of the present study is to establish, in our laboratory, a published model of pharmacologically induced alcohol craving, and carry out an initial evaluation of its predictive validity for efficacy in treatment of alcoholism. Two pharmacological challenges are tested: 1. The alpha2-adrenergic an...	Alcoholism	Chemical Stressor Alcoholism Yohimbine Acamprosate Craving	null	2	arm 1: Subjects received 3 tablets of 333mg acamprosate orally, three times daily (total dose of 999 mg) for a minimum of 2 weeks. arm 2: Subjects received 3 tablets of placebo orally, three times daily, for a minimum of 2 weeks.	[ 0, 2 ]	4	[ 0, 0, 0, 0 ]	intervention 1: orally administered tablet, 333mg, three times daily for a minimum of 2 weeks (14 days) intervention 2: Intravenous infusion of yohimbine (0.4 mg/kg) administered once over 10 minutes intervention 3: Intravenous infusion of mCPP (0.05 mg/kg) over 10 minutes, two times, for a total of 0.1 mg/kg intervent...	intervention 1: Acamprosate intervention 2: Yohimbine intervention 3: mCPP intervention 4: Saline	1	Bethesda \| Maryland \| United States \| -77.10026 \| 38.98067	25	0	0	0	NCT00605904	1COMPLETED	2011-03-01	2008-01-01	National Institute on Alcohol Abuse and Alcoholism (NIAAA)	0NIH	false	false	false	null	0	0	0	0	0
[ 3 ]	4	NA	SINGLE_GROUP	0TREATMENT	0NONE	false	0ALL	true	Background: * Melanoma antigen recognized by T-cells (MART)-1 is a protein present in melanoma cells. * An experimental procedure developed for treating patients with melanoma uses the anti-MART-1 F5 gene and a type of virus to make special cells called anti-MART-1 F5 cells that are designed to destroy the patient's t...	Background: * We have engineered human PBLs to express an anti-MART-1 T-cell receptor that recognizes an human leukocyte antigens (HLA-A) 0201 restricted epitope derived from the tumor infiltrating lymphocytes (TIL) clone DMF5. * We constructed a single retroviral vector that contains both alpha and infinity chains an...	Metastatic Melanoma Skin Cancer	Immunotherapy Metastatic Melanoma Vaccination Tumor Regression Skin Cancer	null	1	arm 1: ALVAC plus anti-MART-1 F5 T cell receptor (TCR ) peripheral blood lymphocytes (PBL) + high dose (HD) interleukin 2 (IL-2): ALVAC vaccine-approximately two hours prior to cell infusion, patients will receive 0.5 mL containing a target dose of 10\^7 cell culture infectious dose 50% (CCID50) (with a range of approx...	[ 0 ]	5	[ 2, 2, 2, 0, 0 ]	intervention 1: ALVAC vaccine-approximately two hours prior to cell infusion, patients will receive 0.5 mL containing a target dose of 10\^7 CCID50 (with a range of approximately 10\^6,4 to 10\^7,9/mL) of the MART-1 ALVAC virus subcutaneously in each extremity (total of 4 x 10\^7 CCID50/2 mL). This will be repeated on ...	intervention 1: autologous anti-MART-1 F5 T-cell receptor gene-engineered peripheral blood lymphocytes intervention 2: ALVAC MART-1 Vaccine intervention 3: aldesleukin intervention 4: cyclophosphamide intervention 5: fludarabine phosphate	1	Bethesda \| Maryland \| United States \| -77.10026 \| 38.98067	4	0	0	0	NCT00612222	6TERMINATED	2011-03-01	2008-01-01	National Cancer Institute (NCI)	0NIH	false	false	false	null	0	0	0	0	0
[ 4 ]	23	RANDOMIZED	PARALLEL	0TREATMENT	0NONE	false	0ALL	false	The planned study focuses on the effect of a one year Somatropin treatment (0.035 mg/kg/d or 0.067 mg/kg/d) in short children born SGA on neuromuscular function and cognitive performance.	null	Growth Hormone Therapy Infant, Small for Gestational Age		null	2	arm 1: Somatropin for 12 months arm 2: In the first 6 months no intervention, afterwards Somatropin for 12 months	[ 1, 5 ]	2	[ 0, 0 ]	intervention 1: Patients will be randomized at baseline in a 1:1 ratio into treatment group or control group. After six months the control group will undergo GH therapy with a higher dose of 0.067 mg/kg/day, too. All patients are treated with growth hormone for 12 months. intervention 2: Patients will be randomized at ...	intervention 1: Somatropin intervention 2: Somatropin	10	Berlin \| N/A \| Germany \| 13.41053 \| 52.52437 Bonn \| N/A \| Germany \| 7.09549 \| 50.73438 Cologne \| N/A \| Germany \| 6.95 \| 50.93333 Datteln \| N/A \| Germany \| 7.3453 \| 51.65598 Dresden \| N/A \| Germany \| 13.73832 \| 51.05089 Erlangen \| N/A \| Germany \| 11.00783 \| 49.59099 Essen \| N/A \| Germany \| 7.01228 \| 51.45657 Heidelberg ...	23	0	0	0	NCT00625872	6TERMINATED	2011-03-01	2008-07-01	Pfizer	4INDUSTRY	false	false	false	null	0	0	0	0	0
[ 2, 3 ]	12	NA	SINGLE_GROUP	0TREATMENT	0NONE	false	0ALL	false	Subjects will be asked to participate in this clinical trial to examine the safety of 2-deoxyglucose (an agent which is quite similar to glucose) in the treatment of solid tumors and hormone refractory prostate cancer. This agent works by blocking the metabolism of glucose in the cells of the body. Although all cells r...	null	Prostate Cancer		null	1	arm 1: None	[ 0 ]	1	[ 0 ]	intervention 1: 30 mg/kg of 2-deoxyglucose administered orally on a daily schedule for two weeks (Days 1-14) of a three week (21 Day) cycle.	intervention 1: 2-deoxyglucose	1	New Brunswick \| New Jersey \| United States \| -74.45182 \| 40.48622	12	0	0	0	NCT00633087	6TERMINATED	2011-03-01	2006-11-01	Rutgers, The State University of New Jersey	7OTHER	false	false	false	null	0	0	0	0	0
[ 3 ]	59	NA	SINGLE_GROUP	0TREATMENT	0NONE	false	0ALL	true	The goal of this study is to determine the activity of sorafenib in patients with advanced (metastatic or recurrent) thyroid cancer.	null	Metastatic Differentiated Thyroid Cancer Metastatic Poorly Differentiated Thyroid Cancer Metastatic Anaplastic Thyroid Cancer Metastatic Medullary Thyroid Cancer	Thyroid Cancer Anaplastic Medullary sorafenib	null	1	arm 1: This is a single arm study.	[ 0 ]	1	[ 0 ]	intervention 1: 400mg PO BID daily	intervention 1: sorafenib	1	Philadelphia \| Pennsylvania \| United States \| -75.16362 \| 39.95238	55	0	0	0	NCT00654238	1COMPLETED	2011-03-01	2006-02-01	University of Pennsylvania	7OTHER	false	false	false	null	0	0	0	0	0
[ 0 ]	1	RANDOMIZED	PARALLEL	4SUPPORTIVE_CARE	0NONE	false	0ALL	null	RATIONALE: Giving medications in different ways may change their effectiveness in controlling pain. It is not yet known whether intrathecal therapy is more effective than standard therapy in controlling pain in patients with pancreatic cancer. PURPOSE: This randomized clinical trial is studying standard pain control t...	OBJECTIVES: Primary * To compare the effectiveness of pain control comprising intrathecal opioid delivery versus the standard analgesia-delivery method in patients with locally advanced, unresectable, or metastatic pancreatic cancer. Secondary * To assess the difference of a total amount of opioid consumption (pare...	Pain Pancreatic Cancer	recurrent pancreatic cancer stage III pancreatic cancer stage IV pancreatic cancer adenocarcinoma of the pancreas pain stage II pancreatic cancer	null	2	arm 1: morphine given traditionally (IV, pill, patch). This is standard of care dosing. arm 2: Pump internal used to deliver morphine. This is a newer method for delivery of morphine. Morphine is FDA approved for intrathecal use. The intrathecal pump will be titrated gradually to effect by the interventional pain medic...	[ 1, 1 ]	2	[ 0, 1 ]	intervention 1: This is morphine given in the traditional methods. intervention 2: This pump will be inserted into the research subject and then the pump will deliver morphine.	intervention 1: morphine sulfate intervention 2: Medtronic intrathecal pump	1	Baltimore \| Maryland \| United States \| -76.61219 \| 39.29038	1	0	0	0	NCT00660348	6TERMINATED	2011-03-01	2008-03-01	Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins	7OTHER	false	false	false	null	0	0	0	0	0
[ 4 ]	120	RANDOMIZED	PARALLEL	0TREATMENT	3TRIPLE	false	0ALL	true	The primary objective is to test the hypothesis that Quetiapine XR (Extended Release) monotherapy and adjunctive therapy is effective in the acute treatment of bipolar depression and comorbid generalized anxiety disorder in patients with bipolar disorder with or without a substance use disorder. The secondary aim is to...	120 subjects aged 18 and up with Diagnostic and Statistical Manual -IV Generalized Anxiety Disorder and Bipolar Disorder type I or II as identified by extensive clinical interview and the Mini-International Neuropsychiatric Interview (MINI) will be enrolled and randomized. Assignment to each arm will be balanced for BP...	Bipolar Disorder Anxiety Anxiety Disorders Substance Use Disorders	Bipolar Disorder Anxiety Anxiety Disorders Substance Use Disorders	null	2	arm 1: Quetiapine XR arm 2: Placebo for quetiapine XR	[ 0, 2 ]	2	[ 0, 0 ]	intervention 1: Days 1-2 - 50 mg/day; Days 3-4 - 150mg/day; Day 5-End of Study - 300mg/day intervention 2: Days 1-2 - 50 mg/day; Days 3-4 - 150mg/day; Day 5-End of Study - 300mg/day	intervention 1: Quetiapine XR intervention 2: Placebo for quetiapine XR	1	Cleveland \| Ohio \| United States \| -81.69541 \| 41.4995	91	0	0	0	NCT00671853	1COMPLETED	2011-03-01	2008-04-01	University Hospitals Cleveland Medical Center	7OTHER	false	false	false	null	0	0	0	0	0
[ 3 ]	8	RANDOMIZED	PARALLEL	0TREATMENT	0NONE	false	0ALL	true	RATIONALE: Drugs used in chemotherapy, such as docetaxel, work in different ways to stop the growth of tumor cells, either by killing the cells or by stopping them from dividing. Vandetanib may stop the growth of tumor cells by blocking some of the enzymes needed for cell growth and by blocking blood flow to the tumor....	OBJECTIVES: Primary * To test the hypothesis that the addition of a targeted agent, such as vandetanib, to standard chemotherapy with docetaxel will result in incremental responses in patients with metastatic gastric or gastroesophageal junction cancer. Secondary * To assess progression-free survival and overall su...	Gastric Cancer	recurrent gastric cancer stage IV gastric cancer adenocarcinoma of the stomach	null	3	arm 1: Patients receive docetaxel IV once every 3 weeks. arm 2: Patients receive docetaxel IV as in arm I and oral vandetanib (100 mg) once daily. arm 3: Patients receive docetaxel IV as in arm I and oral vandetanib (300 mg) once daily.	[ 1, 0, 0 ]	2	[ 0, 0 ]	intervention 1: Given IV once every 3 weeks intervention 2: Oral vandetanib once daily	intervention 1: docetaxel intervention 2: vandetanib	1	Buffalo \| New York \| United States \| -78.87837 \| 42.88645	8	0	0	0	NCT00683787	6TERMINATED	2011-03-01	2008-05-01	Roswell Park Cancer Institute	7OTHER	false	false	false	null	0	0	0	0	0
[ 3 ]	21	NA	SINGLE_GROUP	0TREATMENT	0NONE	false	2MALE	true	Prostatitis is the most common urologic diagnosis in men under the age of 50 and the third most common diagnosis in older men. In Chronic Prostatitis (CP) or Chronic Pelvic Pain Syndrome (CPPS), men have lower urinary tract symptoms, pelvic pain, sexual dysfunction and decreased quality of life. Little is known about t...	Prostatitis is the most common urologic diagnosis in men under the age of 50 and the third most common diagnosis in older men. In Chronic Prostatitis (CP) or Chronic Pelvic Pain Syndrome (CPPS), men have lower urinary tract symptoms, pelvic pain, sexual dysfunction and decreased quality of life. Little is known about ...	Prostatitis Chronic Prostatitis With Chronic Pelvic Pain Syndrome	Prostatitis Pelvic pain	null	1	arm 1: Study drug CC-10004 20mg taken orally twice a day.	[ 0 ]	1	[ 0 ]	intervention 1: CC-10004 20 mg per day	intervention 1: CC-10004	1	Royal Oak \| Michigan \| United States \| -83.14465 \| 42.48948	17	0	0	0	NCT00701311	1COMPLETED	2011-03-01	2008-06-01	Kenneth Peters, MD	7OTHER	false	false	false	null	0	0	0	0	0
[ 4 ]	708	RANDOMIZED	PARALLEL	0TREATMENT	0NONE	false	0ALL	true	The objective of this study is to evaluate the safety of FCM in patients with anemia who are not dialysis dependent.	null	Anemia		null	2	arm 1: 750 mg of iron as undiluted FCM (15 mg/kg up to a maximum of 750 mg) at 100 mg per minute weekly until the calculated iron deficit dose has been administered (to a maximum cumulative dose of 2,250 mg). arm 2: SMC as determined by the Investigator for the treatment of iron deficiency anemia (IDA).	[ 0, 1 ]	2	[ 0, 0 ]	intervention 1: None intervention 2: None	intervention 1: Ferric Carboxymaltose (FCM) intervention 2: Standard Medical Care (SMC) for the treatment of IDA	1	Norristown \| Pennsylvania \| United States \| -75.3399 \| 40.1215	703	0	0	0	NCT00703937	1COMPLETED	2011-03-01	2008-07-01	American Regent, Inc.	4INDUSTRY	false	false	false	null	0	0	0	0	0
[ 4 ]	161	RANDOMIZED	PARALLEL	0TREATMENT	0NONE	false	0ALL	true	The objective of this study is to evaluate the safety of FCM in patients with anemia who are not dialysis dependent.	null	Anemia		null	2	arm 1: 15 mg/kg up to a maximum of 750 mg at 100 mg per minute weekly to a maximum cumulative dose of 2,250 mg. arm 2: As determined by the investigator to a maximum cumulative dose of 2,250 mg.	[ 0, 1 ]	2	[ 0, 0 ]	intervention 1: 15 mg/kg up to a maximum of 750 mg at 100 mg per minute weekly to a maximum cumulative dose of 2,250 mg. intervention 2: As determined by the investigator to a maximum cumulative dose of 2,250 mg.	intervention 1: Ferric Carboxymaltose intervention 2: Iron Dextran	1	Norristown \| Pennsylvania \| United States \| -75.3399 \| 40.1215	160	0	0	0	NCT00704028	1COMPLETED	2011-03-01	2008-06-01	American Regent, Inc.	4INDUSTRY	false	false	false	null	0	0	0	0	0
[ 4 ]	735	RANDOMIZED	PARALLEL	0TREATMENT	0NONE	false	0ALL	true	The objective of this study is to evaluate the safety of FCM in patients with anemia who are not dialysis dependent	null	Anemia		null	2	arm 1: 15 mg/kg up to a maximum of 750 mg at 100 mg/minute intravenously on Day 0. arm 2: Per product label	[ 0, 1 ]	2	[ 0, 0 ]	intervention 1: 15 mg/kg up to a maximum of 750 mg at 100 mg/minute intravenously on Day 0. intervention 2: Per product label	intervention 1: Ferric Carboxymaltose intervention 2: Standard Medical Care (SMC)	1	Norristown \| Pennsylvania \| United States \| -75.3399 \| 40.1215	735	0	0	0	NCT00704353	1COMPLETED	2011-03-01	2008-06-01	American Regent, Inc.	4INDUSTRY	false	false	false	null	0	0	0	0	0
[ 4 ]	680	RANDOMIZED	PARALLEL	0TREATMENT	2DOUBLE	false	0ALL	true	The purpose of this study is to evaluate the benefits and risks of lixisenatide (AVE0010), in comparison to placebo, as an add-on treatment to metformin, over a period of 24 weeks of treatment, followed by an extension. The primary objective is to assess the effects of lixisenatide as an add-on treatment to metformin ...	Patients who complete the 24-week main double-blind treatment would undergo a variable double-blind extension treatment, which ends for all patients at approximately the scheduled date of Week 76 visit (Visit 25) for the last randomized patient.	Diabetes Mellitus, Type 2	hyperglycemia, GLP-1, metformin	null	4	arm 1: 2-step initiation morning regimen of lixisenatide: 10 microgram (mcg) once daily (QD) for 1 week, followed by 15 mcg QD for 1 week, then 20 mcg QD up to end of treatment. arm 2: 2-step initiation evening regimen of lixisenatide: 10 mcg QD for 1 week, followed by 15 mcg QD for 1 week, then 20 mcg QD up to end of ...	[ 0, 0, 2, 2 ]	4	[ 0, 0, 1, 0 ]	intervention 1: Self administered by subcutaneous injections once daily within the hour preceding meal (either breakfast or dinner). intervention 2: Self administered by subcutaneous injections once daily within the hour preceding meal (either breakfast or dinner). intervention 3: None intervention 4: Metformin to be c...	intervention 1: Lixisenatide (AVE0010) intervention 2: Placebo intervention 3: Pen auto-injector intervention 4: Metformin	16	Bridgewater \| New Jersey \| United States \| -74.64815 \| 40.60079 Macquarie Park \| N/A \| Australia \| 151.12757 \| -33.78105 Laval \| N/A \| Canada \| -73.692 \| 45.56995 Santiago \| N/A \| Chile \| -70.64827 \| -33.45694 Zagreb \| N/A \| Croatia \| 15.97798 \| 45.81444 Prague \| N/A \| Czechia \| 14.42076 \| 50.08804 Berlin \| N/A \| Germa...	1,360	0	0	0	NCT00712673	1COMPLETED	2011-03-01	2008-06-01	Sanofi	4INDUSTRY	false	false	false	null	0	0	0	0	0

Subsets and Splits

No community queries yet

The top public SQL queries from the community will appear here once available.